Faculty
Oncology Division
Alphabetical list (active faculty):   
Ravi Vij

Ravi Vij, MD, MBA

Professor

Department of Medicine

Oncology Division

Bone Marrow Transplantation & Leukemia

Research Interests

  • Stem cell transplantation for hematologic malignancy
  • Multiple myeloma
  • Acute myeloid leukemia/myelodysplastic syndromes

Contact

  • 314-454-8304 (office)
  • 314-454-7551 (fax)
  • Division of Oncology
    Mail Stop 8007-0029-11
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • 11th Floor Mid-Campus Center (office)

Peer-reviewed Manuscripts

  • Treatment Outcomes of Triple Class Refractory Multiple Myeloma: A Benchmark for New Therapies
    Bal S, Malek E, Kansagra A, Usmani SZ, Vij R, Godby KN, Cornell RF, Kang Y, Umyarova E, Giri S, Chhabra S, Liedtke M, Callander NS, Hari P, Kumar S, Costa LJ
    Leukemia 2021 Nov 20; [Epub ahead of print]
  • A Single Center Retrospective Study of Daratumumab, Pomalidomide, and Dexamethasone as 2nd-Line Therapy in Multiple Myeloma
    Liu L, Fiala M, Gao F, King J, Goldsmith S, Wildes TM, Stockerl-Goldstein K, Vij R, Schroeder MA
    Leuk Lymphoma 2021 Dec;62(12):3043-3046
  • A Pilot Study of 3D Tissue-Engineered Bone Marrow Culture as a Tool to Predict Patient Response to Therapy in Multiple Myeloma
    Alhallak K, Jeske A, de la Puente P, Sun J, Fiala M, Azab F, Muz B, Sahin I, Vij R, DiPersio JF, Azab AK
    Sci Rep 2021 Sep 29;11(1):19343
  • Quality of Life Analyses in Patients With Multiple Myeloma: Results From the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) Phase 2b Study
    Tremblay G, Daniele P, Breeze J, Li L, Shah J, Shacham S, Kauffman M, Engelhardt M, Chari A, Nooka A, Vogl D, Gavriatopoulou M, Dimopoulos MA, Richardson P, Biran N, Siegel D, Vlummens P, Doyen C, Facon T, Mohty M, Meuleman N, Levy M, Costa L, Hoffman JE, Delforge M, Kaminetzky D, Weisel K, Raab M, Dingli D, Tuchman S, Laurent F, Vij R, Schiller G, Moreau P, Richter J, Schreder M, Podar K, Parker T, Cornell RF, Lionel K, Choquet S, Sundar J
    BMC Cancer 2021 Sep 6;21(1):993
  • Autologous Stem Cell Transplant for Patients With Multiple Myeloma Between Ages 75 and 78
    Fiala MA, King J, Feinberg D, Goldsmith SR, Schroeder MA, Ghobadi A, Stockerl-Goldstein KE, Vij R, Wildes TM
    Bone Marrow Transplant 2021 Aug;56(8):2016-2018
  • Impact of Cytogenetic Abnormalities on Outcomes of Adult Philadelphia-Negative Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research
    Lazaryan A, Dolan M, Zhang MJ, Wang HL, Kharfan-Dabaja MA, Marks DI, Bejanyan N, Copelan E, Majhail NS, Waller EK, Chao N, Prestidge T, Nishihori T, Kebriaei P, Inamoto Y, Hamilton B, Hashmi SK, Kamble RT, Bacher U, Hildebrandt GC, Stiff PJ, McGuirk J, Aldoss I, Beitinjaneh AM, Muffly L, Vij R, Olsson RF, Byrne M, Schultz KR, Aljurf M, Seftel M, Savoie ML, Savani BN, Verdonck LF, Cairo MS, Hossain N, Bhatt VR, Frangoul HA, Abdel-Azim H, Al Malki M, Munker R, Rizzieri D, Khera N, Nakamura R, Ringden O, Van der Poel M, Murthy HS, Liu H, Mori S, De Oliveira S, Bolanos-Meade J, Elsawy M, Barba P, Nathan S, George B, Pawarode A, Grunwald M, Agrawal V, Wang Y, Assal A, Caro PC, Kuwatsuka Y, Seo S, Ustun C, Politikos I, Lazarus HM, Saber W, Sandmaier BM, De Lima M, Litzow M, Bachanova V, Weisdorf D
    Haematologica 2021 Aug 1;106(8):2295-2296
  • Nanoparticle T-Cell Engagers as a Modular Platform for Cancer Immunotherapy
    Alhallak K, Sun J, Wasden K, Guenthner N, O'Neal J, Muz B, King J, Kohnen D, Vij R, Achilefu S, DiPersio JF, Azab AK
    Leukemia 2021 Aug;35(8):2346-2357
  • Evolving Paradigms of Therapy for Multiple Myeloma: State of the Art and Future Directions
    Goldsmith SR, Vij R
    JCO Oncol Pract 2021 Jul;17(7):415-418
  • Phase 3 Randomized Trial of Chemotherapy With or Without Oblimersen in Older AML Patients: CALGB 10201 (Alliance)
    Walker AR, Marcucci G, Yin J, Blum W, Stock W, Kohlschmidt J, Mrozek K, Carroll AJ, Eisfeld AK, Wang ES, Jacobson S, Kolitz JE, Thakuri M, Sutamtewagul G, Vij R, Stuart RK, Byrd JC, Bloomfield CD, Stone RM, Larson RA
    Blood Adv 2021 Jul 13;5(13):2775-2787
  • Co-Evolution of Tumor and Immune Cells During Progression of Multiple Myeloma
    Liu R, Gao Q, Foltz SM, Fowles JS, Yao L, Wang JT, Cao S, Sun H, Wendl MC, Sethuraman S, Weerasinghe A, Rettig MP, Storrs EP, Yoon CJ, Wyczalkowski MA, McMichael JF, Kohnen DR, King J, Goldsmith SR, O'Neal J, Fulton RS, Fronick CC, Ley TJ, Jayasinghe RG, Fiala MA, Oh ST, DiPersio JF, Vij R, Ding L
    Nat Commun 2021 May 7;12(1):2559
  • A Phase 2 Study of Isatuximab Monotherapy in Patients With Multiple Myeloma Who Are Refractory to Daratumumab
    Mikhael J, Belhadj-Merzoug K, Hulin C, Vincent L, Moreau P, Gasparetto C, Pour L, Spicka I, Vij R, Zonder J, Atanackovic D, Gabrail N, Martin TG, Perrot A, Bensfia S, Weng Q, Brillac C, Semiond D, Mace S, Corzo KP, Leleu X
    Blood Cancer J 2021 May 12;11(5):89
  • Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia
    Barnell EK, Newcomer KF, Skidmore ZL, Krysiak K, Anderson SR, Wartman LD, Oh ST, Welch JS, Stockerl-Goldstein KE, Vij R, Cashen AF, Pusic I, Westervelt P, Abboud CN, Ghobadi A, Uy GL, Schroeder MA, DiPersio JF, Politi MC, Spencer DH, Duncavage EJ, Ley TJ, Griffith M, Jacoby MA, Griffith OL
    JCO Precis Oncol 2021 Jan 14;5
  • Isatuximab as Monotherapy and Combined With Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
    Dimopoulos M, Bringhen S, Anttila P, Capra M, Cavo M, Cole C, Gasparetto C, Hungria V, Jenner M, Vorobyev V, Ruiz EY, Yin JY, Saleem R, Hellet M, Mace S, Paiva B, Vij R
    Blood 2021 Mar 4;137(9):1154-1165
  • Renal Failure Among Multiple Myeloma Patients Utilizing Carfilzomib and Associated Factors in the "Real World"
    Mian HS, Fiala MA, Sanchez L, Vij R, Wildes TM
    Ann Hematol 2021 May;100(5):1261-1266
  • A Phase I Trial Evaluating the Effects of Plerixafor, G-CSF, and Azacitidine for the Treatment of Myelodysplastic Syndromes
    Huselton E, Rettig MP, Fletcher T, Ritchey J, Gehrs L, McFarland K, Christ S, Eades WC, Trinkaus K, Romee R, Kulkarni S, Ghobadi A, Abboud C, Cashen AF, Stockerl-Goldstein K, Uy GL, Vij R, Westervelt P, DiPersio JF, Schroeder MA
    Leuk Lymphoma 2021 Jun;62(6):1441-1449
  • VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival
    Fontana F, Scott MJ, Allen JS, Yang X, Cui G, Pan D, Yanaba N, Fiala MA, O'Neal J, Schmieder-Atteberry AH, Ritchey J, Rettig M, Simons K, Fletcher S, Vij R, DiPersio JF, Lanza GM
    Clin Cancer Res 2021 Apr 1;27(7):1974-1986
  • Overall Survival of Patients With Triple-Class Refractory Multiple Myeloma Treated With Selinexor Plus Dexamethasone Vs Standard of Care in MAMMOTH
    Cornell R, Hari P, Tang S, Biran N, Callander N, Chari A, Chhabra S, Fiala MA, Gahvari Z, Gandhi U, Godby K, Gupta R, Jagannath S, Jagosky M, Kang Y, Kansagra A, Kauffman M, Kodali S, Kumar SK, Lakshman A, Liedtke M, Lonial S, Ma X, Malek E, Mansour J, McGehee EF, Neppalli A, Paul B, Richardson P, Scott EC, Shacham S, Shah J, Siegel DS, Umyarova E, Usmani SZ, Varnado W, Vij R, Costa L
    Am J Hematol 2021 Jan;96(1):E5-E8
  • Primary Refractory Multiple Myeloma: A Real-World Experience With 85 Cases
    Jurczyszyn A, Waszczuk-Gajda A, Castillo JJ, Krawczyk K, Stork M, Pour L, Usnarska-Zubkiewicz L, Potoczek S, Hus I, Davila Valls J, Hari P, Chhabra S, Gentile M, Mikala G, Varga G, Chim CS, Fiala M, Vij R, Schutz N, Rodzaj M, Porowska A, Vesole DH, Druzd-Sitek A, Walewski J, Nooka AK
    Leuk Lymphoma 2020 Dec;61(12):2868-2875
  • A Personalized Prediction Model for Outcomes After Allogeneic Hematopoietic Cell Transplant in Patients With Myelodysplastic Syndromes
    Nazha A, Hu ZH, Wang T, Lindsley RC, Abdel-Azim H, Aljurf M, Bacher U, Bashey A, Cahn JY, Cerny J, Copelan E, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla SM, Gale RP, George B, Gergis U, Grunwald MR, Hamilton B, Hashmi S, Hildebrandt GC, Inamoto Y, Kalaycio M, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Liesveld JL, Litzow MR, Majhail NS, Murthy HS, Nathan S, Nishihori T, Pawarode A, Rizzieri D, Sabloff M, Savani BN, Schachter L, Schouten HC, Seo S, Shah NN, Solh M, Valcarcel D, Vij R, Warlick E, Wirk B, Wood WA, Yared JA, Alyea E, Popat U, Sobecks RM, Scott BL, Nakamura R, Saber W
    Biol Blood Marrow Transplant 2020 Nov;26(11):2139-2146
  • African Americans With Translocation t(11;14) Have Superior Survival After Autologous Hematopoietic Cell Transplantation for Multiple Myeloma in Comparison With Whites in the United States
    Badar T, Hari P, Davila O, Fraser R, Wirk B, Dhakal B, Freytes CO, Rodriguez Valdes C, Lee C, Vesole DH, Malek E, Hildebrandt GC, Landau H, Murthy HS, Lazarus HM, Berdeja JG, Meehan KR, Solh M, Diaz MA, Kharfan-Dabaja MA, Callander NS, Farhadfar N, Bashir Q, Kamble RT, Vij R, Munker R, Kyle RA, Chhabra S, Hashmi S, Ganguly S, Jagannath S, Nishihori T, Nieto Y, Kumar S, Shah N, D'Souza A
    Cancer 2020 Jan 1;127(1):82-92
  • Tumor Microenvironment-Targeted Nanoparticles Loaded With Bortezomib and ROCK Inhibitor Improve Efficacy in Multiple Myeloma
    Federico C, Alhallak K, Sun J, Duncan K, Azab F, Sudlow GP, de la Puente P, Muz B, Kapoor V, Zhang L, Yuan F, Markovic M, Kotsybar J, Wasden K, Guenthner N, Gurley S, King J, Kohnen D, Salama NN, Thotala D, Hallahan DE, Vij R, DiPersio JF, Achilefu S, Azab AK
    Nat Commun 2020 Nov 27;11(1):6037
  • Carfilzomib, Lenalidomide, and Dexamethasone Plus Transplant in Newly Diagnosed Multiple Myeloma
    Jasielec JK, Kubicki T, Raje N, Vij R, Reece D, Berdeja J, Derman BA, Rosenbaum CA, Richardson P, Gurbuxani S, Major S, Wolfe B, Stefka AT, Stephens L, Tinari KM, Hycner T, Rojek AE, Dytfeld D, Griffith KA, Zimmerman TM, Jakubowiak AJ
    Blood 2020 Nov 26;136(22):2513-2523
  • Racial Disparities in the Utilization of Novel Agents for Frontline Treatment of Multiple Myeloma
    Fiala MA, Wildes TM, Vij R
    Clin Lymphoma Myeloma Leuk 2020 Oct;20(10):647-651
  • Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States
    Yu Y, Brown Wade N, Hwang AE, Nooka AK, Fiala MA, Mohrbacher A, Peters ES, Pawlish K, Bock C, Van Den Berg DJ, Rand KA, Stram D, Conti DV, Auclair D, Colditz GA, Mehta J, Haiman CA, Terebelo H, Janakiraman N, Singhal S, Chiu B, Vij R, Bernal-Mizrachi L, Zonder JA, Huff CA, Lonial S, Orlowski RZ, Cozen W, Ailawadhi S
    JCO Oncol Pract 2020 Oct;16(10):e1169-e1180
  • Risk Factors for Graft-Versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide
    Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, Abdel-Azim H, Agrawal V, Al-Homsi AS, Aljurf M, Askar M, Auletta JJ, Bashey A, Beitinjaneh A, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Cerny J, Chhabra S, Choe H, Ciurea S, Daly A, Perez MAD, Farhadfar N, Gadalla SM, Gale R, Ganguly S, Gergis U, Hanna R, Hematti P, Herzig R, Hildebrandt GC, Lad DP, Lee C, Lehmann L, Lekakis L, Kamble RT, Kharfan-Dabaja MA, Khandelwal P, Martino R, Murthy HS, Nishihori T, O'Brien TA, Olsson RF, Patel SS, Perales MA, Prestidge T, Qayed M, Romee R, Schoemans H, Seo S, Sharma A, Solh M, Strair R, Teshima T, Urbano-Ispizua A, Van der Poel M, Vij R, Wagner JL, William B, Wirk B, Yared JA, Spellman SR, Arora M, Hamilton BK
    Biol Blood Marrow Transplant 2020 Aug;26(8):1459-1468
  • A Dose-Finding Phase 2 Study of Single Agent Isatuximab (Anti-CD38 MAb) in Relapsed/Refractory Multiple Myeloma
    Mikhael J, Richter J, Vij R, Cole C, Zonder J, Kaufman JL, Bensinger W, Dimopoulos M, Lendvai N, Hari P, Ocio EM, Gasparetto C, Kumar S, Oprea C, Chiron M, Brillac C, Charpentier E, San-Miguel J, Martin T
    Leukemia 2020 Dec;34(12):3298-3309
  • The Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Multiple Myeloma
    Shah N, Aiello J, Avigan DE, Berdeja JG, Borrello IM, Chari A, Cohen AD, Ganapathi K, Gray L, Green D, Krishnan A, Lin Y, Manasanch E, Munshi NC, Nooka AK, Rapoport AP, Smith EL, Vij R, Dhodapkar M
    J Immunother Cancer 2020 Jul;8(2)
  • Long-Term Follow-Up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma
    Holstein SA, Suman VJ, Owzar K, Santo K, Benson DM Jr, Shea TC, Martin T, Silverman M, Isola L, Vij R, Cheson BD, Linker C, Anderson KC, Richardson PG, McCarthy PL
    Biol Blood Marrow Transplant 2020 Aug;26(8):1414-1424
  • Evolution and Structure of Clinically Relevant Gene Fusions in Multiple Myeloma
    Foltz SM, Gao Q, Yoon CJ, Sun H, Yao L, Li Y, Jayasinghe RG, Cao S, King J, Kohnen DR, Fiala MA, Ding L, Vij R
    Nat Commun 2020 May 29;11(1):2666
  • The Characteristics, Treatment Patterns, and Outcomes of Older Adults Aged 80 and Over With Multiple Myeloma
    Fiala MA, Foley NC, Zweegman S, Vij R, Wildes TM
    J Geriatr Oncol 2020 Nov;11(8):1274-1278
  • DCEP and Bendamustine/Prednisone as Salvage Therapy for Quad- and Penta-Refractory Multiple Myeloma
    Goldsmith SR, Fiala MA, Wang B, Schroeder MA, Wildes TM, Ghobadi A, Stockerl-Goldstein K, Vij R
    Ann Hematol 2020 May;99(5):1041-1048
  • The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era
    Schmidt S, Liu Y, Hu ZH, Williams KM, Lazarus HM, Vij R, Kharfan-Dabaja MA, Orti G, Wiernik PH, Weisdorf D, Kamble RT, Herzig R, Wirk B, Cerny J, Bacher U, Chaudhri NA, Nathan S, Farhadfar N, Aljurf M, Gergis U, Szer J, Seo S, Hsu JW, Olsson RF, Maharaj D, George B, Hildebrandt GC, Agrawal V, Nishihori T, Abdel-Azim H, Alyea E, Popat U, Sobecks R, Scott BL, Holter Chakrabarty J, Saber W
    Biol Blood Marrow Transplant 2020 Jun;26(6):1137-1143
  • Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
    Sun J, Muz B, Alhallak K, Markovic M, Gurley S, Wang Z, Guenthner N, Wasden K, Fiala MA, King J, Kohnen D, Salama NN, Vij R, Azab AK
    Cancers (Basel) 2020 Jan 28;12(2)
  • First-In-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients With Relapsed and Refractory Multiple Myeloma
    Vij R, Nath R, Afar DEH, Mateos MV, Berdeja JG, Raab MS, Guenther A, Martinez-Lopez J, Jakubowiak AJ, Leleu X, Weisel K, Wong S, Gulbranson S, Sheridan JP, Reddy A, Paiva B, Singhal A, San-Miguel JF, Moreau P
    Clin Cancer Res 2020 May 15;26(10):2308-2317
  • A Meta-Analysis of Genome-Wide Association Studies of Multiple Myeloma Among Men and Women of African Ancestry
    Du Z, Weinhold N, Song GC, Rand KA, Van Den Berg DJ, Hwang AE, Sheng X, Hom V, Ailawadhi S, Nooka AK, Singhal S, Pawlish K, Peters ES, Bock C, Mohrbacher A, Stram A, Berndt SI, Blot WJ, Casey G, Stevens VL, Kittles R, Goodman PJ, Diver WR, Hennis A, Nemesure B, Klein EA, Rybicki BA, Stanford JL, Witte JS, Signorello L, John EM, Bernstein L, Stroup AM, Stephens OW, Zangari M, Van Rhee F, Olshan A, Zheng W, Hu JJ, Ziegler R, Nyante SJ, Ingles SA, Press MF, Carpten JD, Chanock SJ, Mehta J, Colditz GA, Wolf J, Martin TG, Tomasson M, Fiala MA, Terebelo H, Janakiraman N, Kolonel L, Anderson KC, Le Marchand L, Auclair D, Chiu BC, Ziv E, Stram D, Vij R, Bernal-Mizrachi L, Morgan GJ, Zonder JA, Huff CA, Lonial S, Orlowski RZ, Conti DV, Haiman CA, Cozen W
    Blood Adv 2020 Jan 14;4(1):181-190
  • Measuring Cardiopulmonary Complications of Carfilzomib Treatment and Associated Risk Factors Using the SEER-Medicare Database
    Fakhri B, Fiala MA, Shah N, Vij R, Wildes TM
    Cancer 2020 Feb 15;126(4):808-813
  • Impact of Cytogenetic Abnormalities on Outcomes of Adult Philadelphia-Negative Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research
    Lazaryan A, Dolan M, Zhang MJ, Wang HL, Kharfan-Dabaja MA, Marks DI, Bejanyan N, Copelan E, Majhail NS, Waller EK, Chao N, Prestidge T, Nishihori T, Kebriaei P, Inamoto Y, Hamilton B, Hashmi SK, Kamble RT, Bacher U, Hildebrandt GC, Stiff PJ, McGuirk J, Aldoss I, Beitinjaneh AM, Muffly L, Vij R, Olsson RF, Byrne M, Schultz KR, Aljurf M, Seftel M, Savoie ML, Savani BN, Verdonck LF, Cairo MS, Hossain N, Bhatt VR, Frangoul HA, Abdel-Azim H, Malki MA, Munker R, Rizzieri D, Khera N, Nakamura R, Ringden O, van der Poel M, Murthy HS, Liu H, Mori S, De Oliveira S, Bolanos-Meade J, Elsawy M, Barba P, Nathan S, George B, Pawarode A, Grunwald M, Agrawal V, Wang Y, Assal A, Caro PC, Kuwatsuka Y, Seo S, Ustun C, Politikos I, Lazarus HM, Saber W, Sandmaier BM, De Lima M, Litzow M, Bachanova V, Weisdorf D
    Acute Leukemia Committee of the CIBMTR

    Haematologica 2020 May;105(5):1329-1338
  • Maintenance Therapy Following Salvage Autologous Stem Cell Transplant in Patients With Multiple Myeloma
    Fiala MA, Vosuri V, Goldsmith S, Schroeder MA, Ghobadi A, Wildes TM, Stockerl-Goldstein KE, Vij R
    Bone Marrow Transplant 2020 Jun;55(6):1188-1190
  • Cost Differential Associated With Hospice Use Among Older Patients With Multiple Myeloma
    Fiala MA, Gettinger T, Wallace CL, Vij R, Wildes TM
    J Geriatr Oncol 2020 Jan;11(1):88-92
  • Selinexor Combined With Cladribine, Cytarabine, and Filgrastim in Relapsed or Refractory Acute Myeloid Leukemia
    Abboud R, Chendamarai E, Rettig MP, Trinkaus KM, Riedell PA, Abboud CN, Ghobadi A, Pusic I, Stockerl-Goldstein K, Schroeder MA, Vij R, Westervelt P, DiPersio JF, Uy GL
    Haematologica 2020 Aug;105(8):e404-e407
  • Allogeneic Transplantation in Elderly Patients >/=65 Years With Non-Hodgkin Lymphoma: A Time-Trend Analysis
    Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M
    Blood Cancer J 2019 Dec 3;9(12):97
  • EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms
    Goldsmith SR, Fiala MA, O'Neal J, Souroullas GP, Toama W, Vij R, Schroeder MA
    Clin Lymphoma Myeloma Leuk 2019 Nov;19(11):744-750
  • Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
    Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S
    N Engl J Med 2019 Aug 22;381(8):727-738
  • Inhibition of E-Selectin (GMI-1271) or E-Selectin Together With CXCR4 (GMI-1359) Re-Sensitizes Multiple Myeloma to Therapy
    Muz B, Azab F, Fiala MA, King J, Kohnen D, Fogler WE, Smith T, Magnani JL, Vij R, Azab AK
    Blood Cancer J 2019 Aug 20;9(9):68
  • A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
    Ghobadi A, Fiala MA, Rettig MP, Schroeder MA, Uy GL, Stockerl-Goldstein KE, Westervelt P, Vij R, DiPersio JF
    Clin Lymphoma Myeloma Leuk 2019 Oct;19(10):e588-e593
  • A Mixed-Methods Study of Stem Cell Transplantation Utilization for Newly Diagnosed Multiple Myeloma
    Fiala MA, Vij R, Wildes TM
    Clin Lymphoma Myeloma Leuk 2019 Sep;19(9):e521-e525
  • A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (And Older Patients With Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance)
    Vij R, Le-Rademacher J, Laumann K, Hars V, Owzar K, Shore T, Vasu S, Cashen AF, Isola L, Shea T, DeMagalhaes-Silverman M, Hurd D, Meehan K, Beardell F, Devine S
    Biol Blood Marrow Transplant 2019 Oct;25(10):1984-1992
  • A Phase Ib/II Study of Oprozomib in Patients With Advanced Multiple Myeloma and Waldenstrom Macroglobulinemia
    Ghobrial IM, Vij R, Siegel D, Badros A, Kaufman J, Raje N, Jakubowiak A, Savona MR, Obreja M, Berdeja JG
    Clin Cancer Res 2019 Aug 15;25(16):4907-4916
  • Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation
    Saad A, Lamb L, Wang T, Hemmer MT, Spellman S, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Agrawal V, Aljurf M, Beitinjaneh AM, Bhatt VR, Buchbinder D, Byrne M, Cahn JY, Cairo M, Castillo P, Chhabra S, Diaz MA, Farhan S, Floisand Y, Frangoul HA, Gadalla SM, Gajewski J, Gale RP, Gandhi M, Gergis U, Hamilton BK, Hematti P, Hildebrandt GC, Kamble RT, Kanate AS, Khandelwal P, Lazaryn A, MacMillan M, Marks DI, Martino R, Mehta PA, Nishihori T, Olsson RF, Patel SS, Qayed M, Rangarajan HG, Reshef R, Ringden O, Savani BN, Schouten HC, Schultz KR, Seo S, Shaffer BC, Solh M, Teshima T, Urbano-Ispizua A, Verdonck LF, Vij R, Waller EK, William B, Wirk B, Yared JA, Yu LC, Arora M, Hashmi S
    Biol Blood Marrow Transplant 2019 Sep;25(9):1875-1883
  • A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
    Schroeder MA, Fiala MA, Huselton E, Cardone MH, Jaeger S, Jean SR, Shea K, Ghobadi A, Wildes TM, Stockerl-Goldstein KE, Vij R
    Clin Cancer Res 2019 Jul 1;25(13):3776-3783
  • Phase 1b Trial of Pembrolizumab Monotherapy for Relapsed/Refractory Multiple Myeloma: KEYNOTE-013
    Ribrag V, Avigan DE, Green DJ, Wise-Draper T, Posada JG, Vij R, Zhu Y, Farooqui MZH, Marinello P, Siegel DS
    Br J Haematol 2019 Aug;186(3):e41-e44
  • Outcomes of Patients With Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody Therapy
    Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ
    Leukemia 2019 Sep;33(9):2266-2275
  • Next Generation Sequencing-Based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study
    Goldsmith SR, Fiala MA, Dukeman J, Ghobadi A, Stockerl-Goldstein KE, Schroeder MA, Tomasson M, Wildes TM, Vij R
    Clin Lymphoma Myeloma Leuk 2019 May;19(5):285-289
  • PYK2/FAK Inhibitors Reverse Hypoxia-Induced Drug Resistance in Multiple Myeloma
    Muz B, Buggio M, Azab F, de la Puente P, Fiala MA, Padval MV, Weaver DT, Pachter JA, Vij R, Azab AK
    Haematologica 2019 Jul;104(7):e310-e313
  • Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial
    Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Giralt S, Somlo G, Krishnan A
    J Clin Oncol 2019 Mar 1;37(7):589-597
  • Geriatric Assessment in Older Adults With Multiple Myeloma
    Wildes TM, Tuchman SA, Klepin HD, Mikhael J, Trinkaus K, Stockerl-Goldstein KE, Vij R, Colditz G
    J Am Geriatr Soc 2019 May;67(5):987-991
  • Health Related Quality of Life for Multiple Myeloma Patients According to Treatment Strategy After Autologous Stem Cell Transplant: A Cross-Sectional Study Using EORTC, EQ-5D and MY-20 Scales
    Tay J, Vij R, Norkin M, Buadi F, Kindwall-Keller TL, Roberts JS, White DJ, Wood RP, Blanthorn-Hazell SE, Rossi AC, Dhanasiri S, Zafar F, Newhouse K, McCurdy AR
    Leuk Lymphoma 2019 May;60(5):1275-1282
  • Multiple Myeloma in Patients Up to 30 Years of Age: A Multicenter Retrospective Study of 52 Cases
    Jurczyszyn A, Davila J, Kortum KM, Jayabalan DS, Vij R, Fiala M, Milunovic V, Chim CS, Wisniewska-Piaty K, Waszczuk-Gajda A, Crusoe E, Hajek R, Robak P, Razny M, Zawirska D, Bittrich M, Nahi H, Liu J, Castillo JJ, Vesole DH
    Leuk Lymphoma 2019 Feb;60(2):471-476
  • Secondary Plasma Cell Leukemia: A Multicenter Retrospective Study of 101 Patients
    Jurczyszyn A, Castillo JJ, Avivi I, Czepiel J, Davila J, Vij R, Fiala MA, Gozzetti A, Grzasko N, Milunovic V, Hus I, Madry K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Debski J, Atilla E, Beksac M, Mele G, Sawicki W, Jayabalan D, Charlinski G, Gyula Szabo A, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Crusoe E, Hungria V, Richardson P, Laubach J, Guerrero-Garcia T, Liu J, Vesole DH
    Leuk Lymphoma 2019 Jan;60(1):118-123
  • Propensity Score Matching Analysis to Evaluate the Comparative Effectiveness of Daratumumab Versus Real-World Standard of Care Therapies for Patients With Heavily Pretreated and Refractory Multiple Myeloma
    Kumar S, Durie B, Nahi H, Vij R, Dimopoulos MA, Kastritis E, Terpos E, Leleu X, Beksac M, Goldschmidt H, Hillengass J, Su Z, Hutton B, Cameron C, Khan I, Lam A
    Leuk Lymphoma 2019 Jan;60(1):163-171
  • Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-Versus-Host Disease After Reduced-Intensity Conditioning Allogeneic Transplantation
    Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, Litzow MR, Solh MM, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK
    Biol Blood Marrow Transplant 2019 Jan;25(1):73-85
  • Impact of Elotuzumab Treatment on Pain and Health-Related Quality of Life in Patients With Relapsed or Refractory Multiple Myeloma: Results From the ELOQUENT-2 Study
    Cella D, McKendrick J, Kudlac A, Palumbo A, Oukessou A, Vij R, Zyczynski T, Davis C
    Ann Hematol 2018 Dec;97(12):2455-2463
  • Multiple Myeloma Patients Ineligible for Randomized Controlled Trials Have Poorer Outcomes Irrespective of Treatment
    Malecek MK, Fiala M, Schroeder M, Dukeman J, Ghobadi A, Stockerl-Goldstein K, Wildes T, Vij R
    Clin Lymphoma Myeloma Leuk 2018 Sep;18(9):e363-e364
  • The Efficacy of Salvage Autologous Stem Cell Transplant Among Patients With Multiple Myeloma Who Received Maintenance Therapy Post Initial Transplant
    Manjappa S, Fiala MA, King J, Kohnen DA, Vij R
    Bone Marrow Transplant 2018 Nov;53(11):1483-1486
  • Early Relapse After Autologous Hematopoietic Cell Transplantation Remains a Poor Prognostic Factor in Multiple Myeloma but Outcomes Have Improved Over Time
    Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, Kharfan-Dabaja M, Freytes C, Hashmi S, Hildebrandt G, Holmberg L, Kyle R, Lazarus H, Lee C, Mikhael J, Nishihori T, Tay J, Usmani S, Vesole D, Vij R, Wirk B, Krishnan A, Gasparetto C, Mark T, Nieto Y, Hari P, D'Souza A
    Leukemia 2018 Apr;32(4):986-995
  • Autologous Transplantation Versus Allogeneic Transplantation in Patients With Follicular Lymphoma Experiencing Early Treatment Failure
    Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, Bachanova V, Bacher U, Bashey A, Bolanos-Meade J, Cairo M, Chen A, Chhabra S, Copelan E, Dahi PB, Aljurf M, Farooq U, Ganguly S, Hertzberg M, Holmberg L, Inwards D, Kanate AS, Karmali R, Kenkre VP, Kharfan-Dabaja MA, Klein A, Lazarus HM, Mei M, Mussetti A, Nishihori T, Ramakrishnan Geethakumari P, Saad A, Savani BN, Schouten HC, Shah N, Urbano-Ispizua A, Vij R, Vose J, Sureda A, Hamadani M
    Cancer 2018 Jun 15;124(12):2541-2551
  • Driver Fusions and Their Implications in the Development and Treatment of Human Cancers
    Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, Liao WW, Reynolds SM, Wyczalkowski MA, Yao L, Yu L, Sun SQ, Chen K, Lazar AJ, Fields RC, Wendl MC, Van Tine BA, Vij R, Chen F, Nykter M, Shmulevich I, Ding L
    Fusion Analysis Working Group

    Cell Rep 2018 Apr 3;23(1):227-238e3
  • Lenalidomide Results in a Durable Complete Remission in Acute Myeloid Leukemia Accompanied by Persistence of Somatic Mutations and a T-Cell Infiltrate in the Bone Marrow
    Bansal D, Vij K, Chang GS, Miller CA, DiPersio JF, Vij R, Heath SE, Westervelt P, Welch JS, Fehniger TA
    Haematologica 2018 Jun;103(6):e270-e273
  • A Multiple Myeloma-Specific Capture Sequencing Platform Discovers Novel Translocations and Frequent, Risk-Associated Point Mutations in IGLL5
    White BS, Lanc I, O'Neal J, Gupta H, Fulton RS, Schmidt H, Fronick C, Belter EA Jr., Fiala M, King J, Ahmann GJ, DeRome M, Mardis ER, Vij R, DiPersio JF, Levy J, Auclair D, Tomasson MH
    Blood Cancer J 2018 Mar 21;8(3):35
  • Ibrutinib Alone or With Dexamethasone for Relapsed or Relapsed and Refractory Multiple Myeloma: Phase 2 Trial Results
    Richardson PG, Bensinger WI, Huff CA, Costello CL, Lendvai N, Berdeja JG, Anderson LD Jr., Siegel DS, Lebovic D, Jagannath S, Laubach JP, Stockerl-Goldstein KE, Kwei L, Clow F, Elias L, Salman Z, Graef T, Bilotti E, Vij R
    Br J Haematol 2018 Mar;180(6):821-830
  • Cellular Stressors Contribute to the Expansion of Hematopoietic Clones of Varying Leukemic Potential
    Wong TN, Miller CA, Jotte MRM, Bagegni N, Baty JD, Schmidt AP, Cashen AF, Duncavage EJ, Helton NM, Fiala M, Fulton RS, Heath SE, Janke M, Luber K, Westervelt P, Vij R, DiPersio JF, Welch JS, Graubert TA, Walter MJ, Ley TJ, Link DC
    Nat Commun 2018 Jan 31;9(1):455
  • Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
    Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK
    J Clin Oncol 2018 Mar 20;36(9):859-866
  • Donor Body Mass Index Does Not Predict Graft Versus Host Disease Following Hematopoietic Cell Transplantation
    Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Ahmed I, Beitinjaneh A, Buchbinder D, Byrne M, Callander N, Chao N, Choi SW, DeFilipp Z, Gadalla SM, Gale RP, Gergis U, Hashmi S, Hematti P, Holmberg L, Inamoto Y, Kamble RT, Lehmann L, MacMillan MA, McIver Z, Nishihori T, Norkin M, O'Brien T, Olsson RF, Reshef R, Saad A, Savani BN, Schouten HC, Seo S, Solh M, Verdonck L, Vij R, Wirk B, Yared J, Horowitz MM, Knight JM, Verneris MR
    Bone Marrow Transplant 2018 Jul;53(7):932-937
  • Intravenous Busulfan Compared With Total Body Irradiation Pretransplant Conditioning for Adults With Acute Lymphoblastic Leukemia
    Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ, Sandmaier BM, Horowitz MM, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP, Litzow M, Bredeson C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin R, Forman S, Pullarkat V, Weisdorf D, Marks DI
    Acute Leukemia Committee of the CIBMTR (Contributors include: Vij R)

    Biol Blood Marrow Transplant 2018 Apr;24(4):726-733
  • Enhancing Proteasome-Inhibitory Activity and Specificity of Bortezomib by CD38 Targeted Nanoparticles in Multiple Myeloma
    de la Puente P, Luderer MJ, Federico C, Jin A, Gilson RC, Egbulefu C, Alhallak K, Shah S, Muz B, Sun J, King J, Kohnen D, Salama NN, Achilefu S, Vij R, Azab AK
    J Control Release 2018 Jan 28;270:158-176
  • Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data From Prospective Studies
    Komrokji R, Swern AS, Grinblatt D, Lyons RM, Tobiasson M, Silverman LR, Sayar H, Vij R, Fliss A, Tu N, Sugrue MM
    Oncologist 2018 Feb;23(2):159-170
  • Randomized Study of Continuous High-Dose Lenalidomide, Sequential Azacitidine and Lenalidomide, or Azacitidine in Persons 65 Years and Over With Newly-Diagnosed Acute Myeloid Leukemia
    Medeiros BC, McCaul K, Kambhampati S, Pollyea DA, Kumar R, Silverman LR, Kew A, Saini L, Beach CL, Vij R, Wang X, Zhong J, Gale RP
    Haematologica 2018 Jan;103(1):101-106
  • Preclinical Development of CD38-Targeted [(89)Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma
    Ghai A, Maji D, Cho N, Chanswangphuwana C, Rettig M, Shen D, DiPersio J, Akers W, Dehdashti F, Achilefu S, Vij R, Shokeen M
    J Nucl Med 2018 Feb;59(2):216-222
  • Patterns of Infectious Complications in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients Treated With 10-Day Decitabine Regimen
    Ali AM, Weisel D, Gao F, Uy GL, Cashen AF, Jacoby MA, Wartman LD, Ghobadi A, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Schroeder MA, Westervelt P, DiPersio JF, Welch JS
    Cancer Med 2017 Dec;6(12):2814-2821
  • Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study
    Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM
    Leukemia 2017 Nov;31(11):2443-2448
  • Efficacy of Venetoclax as Targeted Therapy for Relapsed/Refractory t(11;14) Multiple Myeloma
    Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, Facon T, Amiot M, Moreau P, Punnoose EA, Alzate S, Dunbar M, Xu T, Agarwal SK, Enschede SH, Leverson JD, Ross JA, Maciag PC, Verdugo M, Touzeau C
    Blood 2017 Nov 30;130(22):2401-2409
  • CD56bright NK Cells Exhibit Potent Antitumor Responses Following IL-15 Priming
    Wagner JA, Rosario M, Romee R, Berrien-Elliott MM, Schneider SE, Leong JW, Sullivan RP, Jewell BA, Becker-Hapak M, Schappe T, Abdel-Latif S, Ireland AR, Jaishankar D, King JA, Vij R, Clement D, Goodridge J, Malmberg KJ, Wong HC, Fehniger TA
    J Clin Invest 2017 Nov 1;127(11):4042-4058
  • Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
    Lee YS, Liu J, Fricano KA, Webb EM, Toolsie DR, Jones S, Rhoads JA, Vij R, Cashen AF, Abboud CN, Westervelt P, Bartlett NL, DiPersio JF, Kreisel FH, Lim KH
    Biol Blood Marrow Transplant 2017 Dec;23(12):2199-2204
  • Updated Analysis of CALGB (Alliance) 100104 Assessing Lenalidomide Versus Placebo Maintenance After Single Autologous Stem-Cell Transplantation for Multiple Myeloma: A Randomised, Double-Blind, Phase 3 Trial
    Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL
    Lancet Haematol 2017 Sep;4(9):e431-e442
  • Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) Versus Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma and Non-Hodgkin Lymphoma
    Bhamidipati PK, Fiala MA, Grossman BJ, DiPersio JF, Stockerl-Goldstein K, Gao F, Uy GL, Westervelt P, Schroeder MA, Cashen AF, Abboud CN, Vij R
    Biol Blood Marrow Transplant 2017 Dec;23(12):2065-2069
  • Similar Survival Outcomes in Patients With Biclonal Versus Monoclonal Myeloma: A Multi-Institutional Matched Case-Control Study
    Jurczyszyn A, Gozzetti A, Gdula-Argasinska J, Czepiel J, Vij R, Fiala M, Valls DJ, Madry K, Waszczuk-Gajda A, Grosicki S, Barchnicka A, Crusoe E, Hungria V, Gentile M, Mele G, Ksieniewicz M, Vesole DH, Castillo JJ
    Ann Hematol 2017 Oct;96(10):1693-1698
  • Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma
    van Beers EH, van Vliet MH, Kuiper R, de Best L, Anderson KC, Chari A, Jagannath S, Jakubowiak A, Kumar SK, Levy JB, Auclair D, Lonial S, Reece D, Richardson P, Siegel DS, Stewart AK, Trudel S, Vij R, Zimmerman TM, Fonseca R
    Clin Lymphoma Myeloma Leuk 2017 Sep;17(9):555-562
  • Haploidentical Hematopoietic Cell Transplant With Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults With Acute Myeloid Leukemia or Myelodysplastic Syndrome
    Slade M, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Romee R
    Biol Blood Marrow Transplant 2017 Oct;23(10):1736-1743
  • Single Institution Experience With G-CSF Mobilized T-Cell Replete Haploidentical Hematopoietic Cell Transplantation
    Huselton E, Slade M, DiPersio JF, Westervelt P, Vij R, Uy GL, Fehniger TA, Abboud CN, Gao F, Schroeder MA, Romee R
    Bone Marrow Transplant 2017 May;52(5):769-771
  • Tariquidar Sensitizes Multiple Myeloma Cells to Proteasome Inhibitors Via Reduction of Hypoxia-Induced P-Gp-Mediated Drug Resistance
    Muz B, Kusdono HD, Azab F, de la Puente P, Federico C, Fiala M, Vij R, Salama NN, Azab AK
    Leuk Lymphoma 2017 Dec;58(12):2916-2925
  • A Phase 1b Study of Isatuximab Plus Lenalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma
    Martin T, Baz R, Benson DM, Lendvai N, Wolf J, Munster P, Lesokhin AM, Wack C, Charpentier E, Campana F, Vij R
    Blood 2017 Jun 22;129(25):3294-3303
  • Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection
    Cashen AF, Rettig M, Gao F, Smith A, Abboud C, Stockerl-Goldstein K, Vij R, Uy G, Westervelt P, DiPersio J
    Biol Blood Marrow Transplant 2017 Aug;23(8):1282-1289
  • IgM Myeloma: A Multicenter Retrospective Study of 134 Patients
    Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM, Gozzetti A, Gustine JN, Hajek R, Hungria V, Jarkovsky J, Jayabalan D, Laubach JP, Lewicka B, Maisnar V, Manasanch EE, Moreau P, Morgan EA, Nahi H, Niesvizky R, Paba-Prada C, Pika T, Pour L, Reagan JL, Richardson PG, Shah J, Spicka I, Vij R, Waszczuk-Gajda A, Gertz MA
    Am J Hematol 2017 Aug;92(8):746-751
  • Treating Multiple Myeloma Patients With Oral Therapies
    Kumar SK, Vij R, Noga SJ, Berg D, Brent L, Dollar L, Chari A
    Clin Lymphoma Myeloma Leuk 2017 May;17(5):243-251
  • Improved Survival After Acute Graft-Versus-Host Disease Diagnosis in the Modern Era
    Khoury HJ, Wang T, Hemmer MT, Couriel D, Alousi A, Cutler C, Aljurf M, Antin JH, Ayas M, Battiwalla M, Cahn JY, Cairo M, Chen YB, Gale RP, Hashmi S, Hayashi RJ, Jagasia M, Juckett M, Kamble RT, Kharfan-Dabaja M, Litzow M, Majhail N, Miller A, Nishihori T, Qayed M, Schoemans H, Schouten HC, Socie G, Storek J, Verdonck L, Vij R, Wood WA, Yu L, Martino R, Carabasi M, Dandoy C, Gergis U, Hematti P, Solh M, Jamani K, Lehmann L, Savani B, Schultz KR, Wirk BM, Spellman S, Arora M, Pidala J
    Haematologica 2017 May;102(5):958-966
  • Mobilization of Allogeneic Peripheral Blood Stem Cell Donors With Intravenous Plerixafor Mobilizes a Unique Graft
    Schroeder MA, Rettig MP, Lopez S, Christ S, Fiala M, Eades W, Mir FA, Shao J, McFarland K, Trinkaus K, Shannon W, Deych E, Yu J, Vij R, Stockerl-Goldstein K, Cashen AF, Uy GL, Abboud CN, Westervelt P, DiPersio JF
    Blood 2017 May 11;129(19):2680-2692
  • Phase I/II Study of the Novel Proteasome Inhibitor Delanzomib (CEP-18770) for Relapsed and Refractory Multiple Myeloma
    Vogl DT, Martin TG, Vij R, Hari P, Mikhael JR, Siegel D, Wu KL, Delforge M, Gasparetto C
    Leuk Lymphoma 2017 Aug;58(8):1872-1879
  • T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation From Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia
    How J, Slade M, Vu K, DiPersio JF, Westervelt P, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Romee R
    Biol Blood Marrow Transplant 2017 Apr;23(4):648-653
  • Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma
    Ou Y, Doshi S, Nguyen A, Jonsson F, Aggarwal S, Rajangam K, Dimopoulos MA, Stewart AK, Badros A, Papadopoulos KP, Siegel D, Jagannath S, Vij R, Niesvizky R, Graham R, Visich J
    J Clin Pharmacol 2017 May;57(5):663-677
  • Maintenance Versus Induction Therapy Choice on Outcomes After Autologous Transplantation for Multiple Myeloma
    Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P
    Biol Blood Marrow Transplant 2017 Feb;23(2):269-277
  • TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
    Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ
    N Engl J Med 2016 Nov 24;375(21):2023-2036
  • Cytomegalovirus Viremia, Disease, and Impact on Relapse in T-Cell Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide
    Goldsmith SR, Slade M, DiPersio JF, Westervelt P, Lawrence SJ, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Dubberke ER, Trinkaus K, Romee R
    Haematologica 2016 Nov;101(11):e465-e468
  • A Meta-Analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci
    Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH, Ailawadhi S, Singhal S, Pawlish K, Peters ES, Bock CH, Stram A, Van Den Berg DJ, Edlund CK, Conti DV, Zimmerman T, Hwang AE, Huntsman S, Graff J, Nooka A, Kong Y, Pregja SL, Berndt SI, Blot WJ, Carpten J, Casey G, Chu L, Diver WR, Stevens VL, Lieber MR, Goodman PJ, Hennis AJ, Hsing AW, Mehta J, Kittles RA, Kolb S, Klein EA, Leske C, Murphy AB, Nemesure B, Neslund-Dudas C, Strom SS, Vij R, Rybicki BA, Stanford JL, Signorello LB, Witte JS, Ambrosone CB, Bhatti P, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante SJ, Bandera EV, Birmann BM, Ingles SA, Press MF, Atanackovic D, Glenn MJ, Cannon-Albright LA, Jones B, Tricot G, Martin TG, Kumar SK, Wolf JL, Deming Halverson SL, Rothman N, Brooks-Wilson AR, Rajkumar SV, Kolonel LN, Chanock SJ, Slager SL, Severson RK, Janakiraman N, Terebelo HR, Brown EE, De Roos AJ, Mohrbacher AF, Colditz GA, Giles GG, Spinelli JJ, Chiu BC, Munshi NC, Anderson KC, Levy J, Zonder JA, Orlowski RZ, Lonial S, Camp NJ, Vachon CM, Ziv E, Stram DO, Hazelett DJ, Haiman CA, Cozen W
    Cancer Epidemiol Biomarkers Prev 2016 Dec;25(12):1609-1618
  • Phase II Study of Propylene Glycol-Free Melphalan Combined With Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
    Cashen AF, Fletcher T, Ceriotti C, Gao F, Ghobadi A, Vij R, Stockerl-Goldstein K, DiPersio J, Abboud C
    Biol Blood Marrow Transplant 2016 Dec;22(12):2155-2158
  • Phase I Study of Azacitidine Following Donor Lymphocyte Infusion for Relapsed Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation
    Ghobadi A, Choi J, Fiala MA, Fletcher T, Liu J, Eissenberg LG, Abboud C, Cashen A, Vij R, Schroeder MA, Pusic I, Stockerl-Goldstein K, Jacoby M, Uy G, DiPersio J, Westervelt P
    Leuk Res 2016 Oct;49:1-6
  • Severe Cytokine-Release Syndrome After T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated With Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated
    Abboud R, Keller J, Slade M, DiPersio JF, Westervelt P, Rettig MP, Meier S, Fehniger TA, Abboud CN, Uy GL, Vij R, Trinkaus KM, Schroeder MA, Romee R
    Biol Blood Marrow Transplant 2016 Oct;22(10):1851-60
  • Proteasome Inhibitor Associated Thrombotic Microangiopathy
    Yui JC, Van Keer J, Weiss BM, Waxman AJ, Palmer MB, D'Agati VD, Kastritis E, Dimopoulos MA, Vij R, Bansal D, Dingli D, Nasr SH, Leung N
    Am J Hematol 2016 Sep;91(9):E348-52
  • Clinical Activity of Carfilzomib Correlates With Inhibition of Multiple Proteasome Subunits: Application of a Novel Pharmacodynamic Assay
    Lee SJ, Levitsky K, Parlati F, Bennett MK, Arastu-Kapur S, Kellerman L, Woo TF, Wong AF, Papadopoulos KP, Niesvizky R, Badros AZ, Vij R, Jagannath S, Siegel D, Wang M, Ahmann GJ, Kirk CJ
    Br J Haematol 2016 Jun;173(6):884-95
  • Newly Established Myeloma-Derived Stromal Cell Line MSP-1 Supports Multiple Myeloma Proliferation, Migration, and Adhesion and Induces Drug Resistance More Than Normal-Derived Stroma
    de la Puente P, Quan N, Hoo RS, Muz B, Gilson RC, Luderer M, King J, Achilefu S, Salama NN, Vij R, Azab AK
    Haematologica 2016 Jul;101(7):e307-11
  • A Study of High-Dose Lenalidomide Induction and Low-Dose Lenalidomide Maintenance Therapy for Patients With Hypomethylating Agent Refractory Myelodysplastic Syndrome
    Cherian MA, Tibes R, Gao F, Fletcher T, Fiala M, Uy GL, Westervelt P, Jacoby MA, Cashen AF, Stockerl-Goldstein K, DiPersio JF, Vij R
    Leuk Lymphoma 2016 Nov;57(11):2535-2540
  • Post-Transplant High-Dose Cyclophosphamide After HLA-Matched Vs Haploidentical Hematopoietic Cell Transplantation for AML
    Rashidi A, Slade M, DiPersio JF, Westervelt P, Vij R, Romee R
    Bone Marrow Transplant 2016 Dec;51(12):1561-1564
  • Comparison of Outcomes After Peripheral Blood Haploidentical Versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia: A Retrospective Single-Center Review
    Rashidi A, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Cashen AF, Fehniger TA, Romee R
    Biol Blood Marrow Transplant 2016 Sep;22(9):1696-701
  • Do Adults Aged 70 Years or Older With Acute Myeloid Leukemia Benefit From Allogeneic Hematopoietic Cell Transplantation?
    Rashidi A, DiPersio JF, Westervelt P, Vij R, Abboud CN, Romee R
    Leukemia 2016 Aug;30(8):1797-9
  • Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
    Shaffer BC, Ahn KW, Hu ZH, Nishihori T, Malone AK, Valcarcel D, Grunwald MR, Bacher U, Hamilton B, Kharfan-Dabaja MA, Saad A, Cutler C, Warlick E, Reshef R, Wirk BM, Sabloff M, Fasan O, Gerds A, Marks D, Olsson R, Wood WA, Costa LJ, Miller AM, Cortes J, Daly A, Kindwall-Keller TL, Kamble R, Rizzieri DA, Cahn JY, Gale RP, William B, Litzow M, Wiernik PH, Liesveld J, Savani BN, Vij R, Ustun C, Copelan E, Popat U, Kalaycio M, Maziarz R, Alyea E, Sobecks R, Pavletic S, Tallman M, Saber W
    J Clin Oncol 2016 Jun 1;34(16):1864-71
  • Chemotherapy Versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Stem Cell Transplant
    Motabi IH, Ghobadi A, Liu J, Schroeder M, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, DiPersio JF
    Biol Blood Marrow Transplant 2016 Jul;22(7):1324-9
  • Central Nervous System Involvement by Multiple Myeloma: A Multi-Institutional Retrospective Study of 172 Patients in Daily Clinical Practice
    Jurczyszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, Crusoe E, Silva Dias AL, Vij R, Fiala MA, Caers J, Rasche L, Nooka AK, Lonial S, Vesole DH, Philip S, Gangatharan S, Druzd-Sitek A, Walewski J, Corso A, Cocito F, Vekemans MC, Atilla E, Beksac M, Leleu X, Davila J, Badros A, Aneja E, Abildgaard N, Kastritis E, Fantl D, Schutz N, Pika T, Butrym A, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Usmani SZ, Nahi H, Chim CS, Shustik C, Madry K, Lentzsch S, Swiderska A, Helbig G, Guzicka-Kazimierczak R, Lendvai N, Waage A, Andersen KT, Murakami H, Zweegman S, Castillo JJ
    Am J Hematol 2016 Jun;91(6):575-80
  • Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study
    Berdeja J, Jagannath S, Zonder J, Badros A, Kaufman JL, Manges R, Gupta M, Tendolkar A, Lynch M, Bleickardt E, Paliwal P, Vij R
    Clin Lymphoma Myeloma Leuk 2016 Mar;16(3):129-38
  • TAK-228 (Formerly MLN0128), an Investigational Oral Dual TORC1/2 Inhibitor: A Phase I Dose Escalation Study in Patients With Relapsed or Refractory Multiple Myeloma, Non-Hodgkin Lymphoma, or Waldenstrom's Macroglobulinemia
    Ghobrial IM, Siegel DS, Vij R, Berdeja JG, Richardson PG, Neuwirth R, Patel CG, Zohren F, Wolf JL
    Am J Hematol 2016 Jun;91(4):400-5
  • A CD138-Independent Strategy to Detect Minimal Residual Disease and Circulating Tumour Cells in Multiple Myeloma
    Muz B, de la Puente P, Azab F, Luderer MJ, King J, Vij R, Azab AK
    Br J Haematol 2016 Apr;173(1):70-81
  • Pediatric-Inspired Therapy Compared to Allografting for Philadelphia Chromosome-Negative Adult ALL in First Complete Remission
    Seftel MD, Neuberg D, Zhang MJ, Wang HL, Ballen KK, Bergeron J, Couban S, Freytes CO, Hamadani M, Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Paulson K, Saber W, Sallan SE, Soiffer R, Tallman MS, Woolfrey AE, DeAngelo DJ, Weisdorf DJ
    Am J Hematol 2016 Mar;91(3):322-9
  • A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia
    Wartman LD, Fiala MA, Fletcher T, Hawkins ER, Cashen A, DiPersio JF, Jacoby MA, Stockerl-Goldstein KE, Pusic I, Uy GL, Westervelt P, Vij R
    Leuk Lymphoma 2016 Mar;57(3):728-730
  • A Phase Ib Study of the Combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma
    Rosenthal A, Kumar S, Hofmeister C, Laubach J, Vij R, Dueck A, Gano K, Stewart AK
    Br J Haematol 2016 Jul;174(2):323-5
  • A Phase I Study of Thymoglobulin for Relapsed or Refractory Multiple Myeloma
    Keller J, Fiala MA, DiPersio J, Stockerl-Goldstein K, Vij R, Heldermon CD
    Leuk Lymphoma 2016 Feb;57(2):453-5
  • Elotuzumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma: Final Phase 2 Results From the Randomised, Open-Label, Phase 1b-2 Dose-Escalation Study
    Richardson PG, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, Vij R, White D, Reece DE, Benboubker L, Zonder J, Tsao LC, Anderson KC, Bleickardt E, Singhal AK, Lonial S
    1703 study investigators

    Lancet Haematol 2015 Dec;2(12):e516-27
  • A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use
    Jonsson F, Ou Y, Claret L, Siegel D, Jagannath S, Vij R, Badros A, Aggarwal S, Bruno R
    CPT Pharmacometrics Syst Pharmacol 2015 Dec;4(12):711-719
  • Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103/Blood and Marrow Transplant Clinical Trial Network 0502
    Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, Champlin RE, Chen YB, Vij R, Slack J, Soiffer RJ, Larson RA, Shea TC, Hars V, Sibley AB, Giralt S, Carter S, Horowitz MM, Linker C, Alyea EP
    J Clin Oncol 2015 Dec 10;33(35):4167-4175
  • Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed And/Or Refractory Multiple Myeloma
    Squifflet P, Michiels S, Siegel D, Vij R, Jagannath S, Saad ED, Rajangam K, Ro SK, Buyse M
    Clin Lymphoma Myeloma Leuk 2015 Nov;15(11):680-6
  • 3D Tissue-Engineered Bone Marrow as a Novel Model to Study Pathophysiology and Drug Resistance in Multiple Myeloma
    de la Puente P, Muz B, Gilson RC, Azab F, Luderer M, King J, Achilefu S, Vij R, Azab AK
    Biomaterials 2015 Dec;73:70-84
  • Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors
    Klyuchnikov E, Bacher U, Kroger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M
    Biol Blood Marrow Transplant 2015 Dec;21(12):2091-2099
  • Bendamustine, Lenalidomide, and Dexamethasone (BRD) Is Highly Effective With Durable Responses in Relapsed Multiple Myeloma
    Kumar SK, Krishnan A, LaPlant B, Laumann K, Roy V, Zimmerman T, Gertz MA, Buadi FK, Stockerl Goldstein K, Birgin A, Fiala M, Duarte L, Maharaj M, Levy J, Vij R
    Am J Hematol 2015 Dec;90(12):1106-10
  • Haploidentical Transplant With Posttransplant Cyclophosphamide Vs Matched Unrelated Donor Transplant for Acute Myeloid Leukemia
    Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, Armand P, Antin JH, Chen J, Devine SM, Fowler DH, Luznik L, Nakamura R, O'Donnell PV, Perales MA, Pingali SR, Porter DL, Riches MR, Ringden OT, Rocha V, Vij R, Weisdorf DJ, Champlin RE, Horowitz MM, Fuchs EJ, Eapen M
    Blood 2015 Aug 20;126(8):1033-40
  • Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types
    Amend SR, Wilson WC, Chu L, Lu L, Liu P, Serie D, Su X, Xu Y, Wang D, Gramolini A, Wen XY, O'Neal J, Hurchla M, Vachon CM, Colditz G, Vij R, Weilbaecher KN, Tomasson MH
    PLoS One 2015 May 28;10(5):e0127828
  • Maintenance Therapy With Decitabine After Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
    Pusic I, Choi J, Fiala MA, Gao F, Holt M, Cashen AF, Vij R, Abboud CN, Stockerl-Goldstein KE, Jacoby MA, Uy GL, Westervelt P, DiPersio JF
    Biol Blood Marrow Transplant 2015 Oct;21(10):1761-9
  • High-Dose Therapy and Autologous Stem Cell Transplant in Older Adults With Multiple Myeloma
    Wildes TM, Finney JD, Fiala M, Gao F, Vij R, Stockerl-Goldstein K, Carson KR, Mikhael J, Colditz G
    Bone Marrow Transplant 2015 Aug;50(8):1075-82
  • Hematologic Recovery After Pretransplant Chemotherapy Does Not Influence Survival After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients
    Vu K, Manjappa S, DiPersio JF, Gao F, Westervelt P, Vij R, Stockerl-Goldstein KE, Uy GL, Abboud CN, Schroeder MA, Fehniger TA, Cashen AF, Romee R
    Biol Blood Marrow Transplant 2015 Aug;21(8):1425-30
  • Phase 1/2 Study of Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Palbociclib (PD-0332991) With Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA, Haideri NA, Yacoub A, Hess G, Lentzsch S, Spicka I, Chanan-Khan AA, Raab MS, Tarantolo S, Vij R, Zonder JA, Huang X, Jayabalan D, Di Liberto M, Huang X, Jiang Y, Kim ST, Randolph S, Chen-Kiang S
    Leuk Lymphoma 2015 Dec;56(12):3320-3328
  • Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma
    Fiala MA, Finney JD, Stockerl-Goldstein KE, Tomasson MH, DiPersio JF, Vij R, Wildes TM
    Biol Blood Marrow Transplant 2015 Jul;21(7):1153-4
  • Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines From the American Society for Blood and Marrow Transplantation
    Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, Sengsayadeth S, Abidi M, Hari P, Mohty M, Chen YB, Koreth J, Landau H, Lazarus H, Leather H, Majhail N, Nath R, Osman K, Perales MA, Schriber J, Shaughnessy P, Vesole D, Vij R, Wingard J, Giralt S, Savani BN
    Biol Blood Marrow Transplant 2015 Jul;21(7):1155-1166
  • Serum Free Light Chain Reduction Correlates With Response and Progression-Free Survival Following Carfilzomib Therapy in Relapsed/Refractory Multiple Myeloma
    Vij R, Wang M, Jagannath S, Niesvizky R, Jakubowiak AJ, Kavalerchik E, Huang M, Siegel DS
    Leuk Lymphoma 2015 Oct;56(10):2959-2961
  • Personalization of Cancer Treatment Using Predictive Simulation
    Doudican NA, Kumar A, Singh NK, Nair PR, Lala DA, Basu K, Talawdekar AA, Sultana Z, Tiwari KK, Tyagi A, Abbasi T, Vali S, Vij R, Fiala M, King J, Perle M, Mazumder A
    J Transl Med 2015 Feb 1;13:43
  • Socioeconomic Status Is Independently Associated With Overall Survival in Patients With Multiple Myeloma
    Fiala MA, Finney JD, Liu J, Stockerl-Goldstein KE, Tomasson MH, Vij R, Wildes TM
    Leuk Lymphoma 2015 Sep;56(9):2643-9
  • Comparative Effectiveness on Survival of Zoledronic Acid Versus Pamidronate in Multiple Myeloma
    Sanfilippo KM, Gage B, Luo S, Weilbaecher K, Tomasson M, Vij R, Colditz G, Carson K
    Leuk Lymphoma 2015 Mar;56(3):615-21
  • Impact of Pretransplant Therapy and Depth of Disease Response Before Autologous Transplantation for Multiple Myeloma
    Vij R, Kumar S, Zhang MJ, Zhong X, Huang J, Dispenzieri A, Abidi MH, Bird JM, Freytes CO, Gale RP, Kindwall-Keller TL, Kyle RA, Landsburg DJ, Lazarus HM, Munker R, Roy V, Sharma M, Vogl DT, Wirk B, Hari PN
    Biol Blood Marrow Transplant 2015 Feb;21(2):335-41
  • Long-Term Survival After Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy
    Eapen M, Logan BR, Appelbaum FR, Antin JH, Anasetti C, Couriel DR, Chen J, Maziarz RT, McCarthy PL, Nakamura R, Ratanatharathorn V, Vij R, Champlin RE
    Biol Blood Marrow Transplant 2015 Jan;21(1):55-9
  • SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution
    Miller CA, White BS, Dees ND, Griffith M, Welch JS, Griffith OL, Vij R, Tomasson MH, Graubert TA, Walter MJ, Ellis MJ, Schierding W, DiPersio JF, Ley TJ, Mardis ER, Wilson RK, Ding L
    PLoS Comput Biol 2014 Aug 7;10(8):e1003665
  • Effect of Age on the Pharmacokinetics of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation; an Alliance Study (CALGB 10503, 19808, and 100103)
    Beumer JH, Owzar K, Lewis LD, Jiang C, Holleran JL, Christner SM, Blum W, Devine S, Kolitz JE, Linker C, Vij R, Alyea EP, Larson RA, Ratain MJ, Egorin MJ
    Cancer Chemother Pharmacol 2014 Nov;74(5):927-38
  • Proteasome Inhibitors Evoke Latent Tumor Suppression Programs in Pro-B MLL Leukemias Through MLL-AF4
    Liu H, Westergard TD, Cashen A, Piwnica-Worms DR, Kunkle L, Vij R, Pham CG, DiPersio J, Cheng EH, Hsieh JJ
    Cancer Cell 2014 Apr 14;25(4):530-42
  • Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Elderly Patients With Newly Diagnosed Multiple Myeloma
    Dytfeld D, Jasielec J, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R, Jakubowiak AJ
    Haematologica 2014 Sep;99(9):e162-4
  • A Phase II Study of V-BEAM as Conditioning Regimen Before Second Auto-SCT for Multiple Myeloma
    Wang TF, Fiala MA, Cashen AF, Uy GL, Abboud CN, Fletcher T, Wu N, Westervelt P, DiPersio JF, Stockerl-Goldstein KE, Vij R
    Bone Marrow Transplant 2014 Nov;49(11):1366-70
  • Vatalanib Population Pharmacokinetics in Patients With Myelodysplastic Syndrome: CALGB 10105 (Alliance)
    Wang X, Owzar K, Gupta P, Larson RA, Mulkey F, Miller AA, Lewis LD, Hurd D, Vij R, Ratain MJ, Murry DJ
    Alliance for Clinical Trials in Oncology

    Br J Clin Pharmacol 2014 Nov;78(5):1005-13
  • Allotransplantation for Patients Age >/=40 Years With Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival
    McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, Deol A, Freytes CO, Hamadani M, Holmberg LA, Jagasia MH, Jakubowski AA, Kharfan-Dabaja MA, Lazarus HM, Miller AM, Olsson R, Pedersen TL, Pidala J, Pulsipher MA, Rowe JM, Saber W, van Besien KW, Waller EK, Aljurf MD, Akpek G, Bacher U, Chao NJ, Chen YB, Cooper BW, Dehn J, de Lima MJ, Hsu JW, Lewis ID, Marks DI, McGuirk J, Cairo MS, Schouten HC, Szer J, Ramanathan M, Savani BN, Seftel M, Socie G, Vij R, Warlick ED, Weisdorf DJ
    Biol Blood Marrow Transplant 2014 Jul;20(7):960-8
  • A Phase I Dose Escalation Study of Oral Bexarotene in Combination With Intravenous Decitabine in Patients With AML
    Welch JS, Niu H, Uy GL, Westervelt P, Abboud CN, Vij R, Stockerl-Goldstein KE, Jacoby M, Pusic I, Schroeder MA, DiPersio JF, Cashen AF
    Am J Hematol 2014 Aug;89(8):E103-8
  • Haploidentical Transplantation Using G-CSF-Mobilized T-Cell Replete PBSCs and Post-Transplantation CY After Non-Myeloablative Conditioning Is Safe and Is Associated With Favorable Outcomes
    Bhamidipati PK, DiPersio JF, Stockerl-Goldstein K, Rashidi A, Gao F, Uy GL, Westervelt P, Vij R, Schroeder MA, Abboud CN, Keller JW, Fehniger TA, Romee R
    Bone Marrow Transplant 2014 Aug;49(8):1124-6
  • Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
    Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knoechel B, Gould J, Saksena G, Cibulskis K, McKenna A, Chapman MA, Straussman R, Levy J, Perkins LM, Keats JJ, Schumacher SE, Rosenberg M, Getz G, Golub TR (Collaborators include: Vij R)
    Cancer Cell 2014 Jan 13;25(1):91-101
  • Recombinant Interleukin-2 in Patients Aged Younger Than 60 Years With Acute Myeloid Leukemia in First Complete Remission: Results From Cancer and Leukemia Group B 19808
    Kolitz JE, George SL, Benson DM Jr, Maharry K, Marcucci G, Vij R, Powell BL, Allen SL, Deangelo DJ, Shea TC, Stock W, Bakan CE, Hars V, Hoke E, Bloomfield CD, Caligiuri MA, Larson RA
    Cancer 2014 Apr 1;120(7):1010-7
  • Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older With Acute Myeloid Leukemia
    Jacoby MA, Martin MG, Uy GL, Westervelt P, DiPersio JF, Cashen A, Stockerl-Goldstein K, Vij R, Luo J, Reineck T, Bernabe N, Abboud CN
    Am J Hematol 2014 May;89(5):487-92
  • Phase I Study of Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor (CLAG Regimen) and Midostaurin and All-Trans Retinoic Acid in Relapsed/Refractory AML
    Ramsingh G, Westervelt P, McBride A, Stockerl-Goldstein K, Vij R, Fiala M, Uy G, Cashen A, DiPersio JF, Abboud CN
    Int J Hematol 2014 Mar;99(3):272-8
  • Pomalidomide Alone or in Combination With Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma: A Randomized Phase 2 Study
    Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson KC
    Blood 2014 Mar 20;123(12):1826-32
  • PI3KCA Plays a Major Role in Multiple Myeloma and Its Inhibition With BYL719 Decreases Proliferation, Synergizes With Other Therapies and Overcomes Stroma-Induced Resistance
    Azab F, Vali S, Abraham J, Potter N, Muz B, de la Puente P, Fiala M, Paasch J, Sultana Z, Tyagi A, Abbasi T, Vij R, Azab AK
    Br J Haematol 2014 Apr;165(1):89-101
  • Effect of Postremission Therapy Before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission
    Warlick ED, Paulson K, Brazauskas R, Zhong X, Miller AM, Camitta BM, George B, Savani BN, Ustun C, Marks DI, Waller EK, Baron F, Freytes CO, Socie G, Akpek G, Schouten HC, Lazarus HM, Horwitz EM, Koreth J, Cahn JY, Bornhauser M, Seftel M, Cairo MS, Laughlin MJ, Sabloff M, Ringden O, Gale RP, Kamble RT, Vij R, Gergis U, Mathews V, Saber W, Chen YB, Liesveld JL, Cutler CS, Ghobadi A, Uy GL, Eapen M, Weisdorf DJ, Litzow MR
    Biol Blood Marrow Transplant 2014 Feb;20(2):202-8
  • Ph+ ALL Patients in First Complete Remission Have Similar Survival After Reduced Intensity and Myeloablative Allogeneic Transplantation: Impact of Tyrosine Kinase Inhibitor and Minimal Residual Disease
    Bachanova V, Marks DI, Zhang MJ, Wang H, de Lima M, Aljurf MD, Arellano M, Artz AS, Bacher U, Cahn JY, Chen YB, Copelan EA, Drobyski WR, Gale RP, Greer JP, Gupta V, Hale GA, Kebriaei P, Lazarus HM, Lewis ID, Lewis VA, Liesveld JL, Litzow MR, Loren AW, Miller AM, Norkin M, Oran B, Pidala J, Rowe JM, Savani BN, Saber W, Vij R, Waller EK, Wiernik PH, Weisdorf DJ
    Leukemia 2014 Mar;28(3):658-65
  • Protective Effect of Cytomegalovirus Reactivation on Relapse After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen
    Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, DiPersio JF, Uy GL, Westervelt P, Liu J, Schroeder MA, Vij R, Abboud CN, Fehniger TA, Cashen AF, Pusic I, Jacoby M, Meera SJ, Romee R
    Biol Blood Marrow Transplant 2014 Jan;20(1):46-52
  • Deep Sequencing Reveals Myeloma Cells in Peripheral Blood in Majority of Multiple Myeloma Patients
    Vij R, Mazumder A, Klinger M, O'Dea D, Paasch J, Martin T, Weng L, Park J, Fiala M, Faham M, Wolf J
    Clin Lymphoma Myeloma Leuk 2014 Apr;14(2):131-139e1
  • The Characteristics and Outcomes of Patients With Multiple Myeloma Dual Refractory or Intolerant to Bortezomib and Lenalidomide in the Era of Carfilzomib and Pomalidomide
    Wang TF, Ahluwalia R, Fiala MA, Trinkaus KM, Cox DP, Jaenicke M, Moliske CC, Carson KR, Wildes TM, Tomasson MH, Stockerl-Goldstein KE, Vij R
    Leuk Lymphoma 2014 Feb;55(2):337-41
  • Germinal Center B-Cells Resist Transformation by Kras Independently of Tumor Suppressor Arf
    Mullins CD, Su MY, Hucthagowder V, Chu L, Lu L, Kulkarni S, Novack D, Vij R, Tomasson MH
    PLoS One 2013 Jun 25;8(6):e67941
  • Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma
    Costa LJ, Zhang MJ, Zhong X, Dispenzieri A, Lonial S, Krishnan A, Freytes C, Vesole D, Gale RP, Anderson K, Wirk B, Savani BN, Waller EK, Schouten H, Lazarus H, Meehan K, Sharma M, Kamble R, Vij R, Kumar S, Nishihori T, Kindwall-Keller T, Saber W, Hari PN
    Biol Blood Marrow Transplant 2013 Nov;19(11):1615-24
  • Integrated Safety Profile of Single-Agent Carfilzomib: Experience From 526 Patients Enrolled in 4 Phase II Clinical Studies
    Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K, Lonial S
    Haematologica 2013 Nov;98(11):1753-61
  • Treatment Outcomes in Patients With Relapsed and Refractory Multiple Myeloma and High-Risk Cytogenetics Receiving Single-Agent Carfilzomib in the PX-171-003-A1 Study
    Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S
    Leukemia 2013 Dec;27(12):2351-6
  • A Phase II Study of the Oral VEGF Receptor Tyrosine Kinase Inhibitor Vatalanib (PTK787/ZK222584) in Myelodysplastic Syndrome: Cancer and Leukemia Group B Study 10105 (Alliance)
    Gupta P, Mulkey F, Hasserjian RP, Sanford BL, Vij R, Hurd DD, Odenike OM, Bloomfield CD, Owzar K, Stone RM, Larson RA
    Invest New Drugs 2013 Oct;31(5):1311-20
  • Influence of Body Mass Index on Survival in Veterans With Multiple Myeloma
    Beason TS, Chang SH, Sanfilippo KM, Luo S, Colditz GA, Vij R, Tomasson MH, DiPersio JF, Stockerl-Goldstein K, Ganti A, Wildes T, Carson KR
    Oncologist 2013;18(10):1074-9
  • Lenalidomide-Mediated Enhanced Translation of C/EBPalpha-P30 Protein Up-Regulates Expression of the Antileukemic MicroRNA-181a in Acute Myeloid Leukemia
    Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Alachkar H, Maharry K, Nicolet D, Mrozek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu LC, Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, Marcucci G
    Blood 2013 Jan 3;121(1):159-69
  • Carfilzomib in Multiple Myeloma Patients With Renal Impairment: Pharmacokinetics and Safety
    Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R
    Leukemia 2013 Aug;27(8):1707-14
  • A Phase 1 Study of Concomitant High-Dose Lenalidomide and 5-Azacitidine Induction in the Treatment of AML
    Ramsingh G, Westervelt P, Cashen AF, Uy GL, Stockerl-Goldstein K, Abboud CN, Bernabe N, Monahan R, DiPersio JF, Vij R
    Leukemia 2013 Mar;27(3):725-8
  • The Epoxyketone-Based Proteasome Inhibitors Carfilzomib and Orally Bioavailable Oprozomib Have Anti-Resorptive and Bone-Anabolic Activity in Addition to Anti-Myeloma Effects
    Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, Collins L, Kirk CJ, Piwnica-Worms D, Vij R, Tomasson MH, Pandiella A, San Miguel JF, Garayoa M, Weilbaecher KN
    Leukemia 2013 Feb;27(2):430-40
  • An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma
    Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DS
    Clin Lymphoma Myeloma Leuk 2012 Oct;12(5):310-8
  • Oral Valganciclovir Versus Ganciclovir as Delayed Pre-Emptive Therapy for Patients After Allogeneic Hematopoietic Stem Cell Transplant: A Pilot Trial (04-0274) and Review of the Literature
    Chawla JS, Ghobadi A, Mosley J 3rd, Verkruyse L, Trinkaus K, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Uy GL, Westervelt P, DiPersio JF, Vij R
    Transpl Infect Dis 2012 Jun;14(3):259-67
  • A Phase 2 Study of Single-Agent Carfilzomib (PX-171-003-A1) in Patients With Relapsed and Refractory Multiple Myeloma
    Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S
    Blood 2012 Oct 4;120(14):2817-25
  • Multiple Myeloma-Associated Chromosomal Translocation Activates Orphan snoRNA ACA11 to Suppress Oxidative Stress
    Chu L, Su MY, Maggi LB Jr, Lu L, Mullins C, Crosby S, Huang G, Chng WJ, Vij R, Tomasson MH
    J Clin Invest 2012 Aug 1;122(8):2793-806
  • Resequencing Analysis of the Candidate Tyrosine Kinase and RAS Pathway Gene Families in Multiple Myeloma
    Hucthagowder V, Meyer R, Mullins C, Nagarajan R, Dipersio JF, Vij R, Tomasson MH, Kulkarni S
    Cancer Genet 2012 Sep;205(9):474-8
  • New Treatment Approaches for Older Adults With Multiple Myeloma
    Wildes TM, Vij R, Petersdorf SH, Medeiros BC, Hurria A
    J Geriatr Oncol 2012 Jul;3(3):279-290
  • An Open-Label, Single-Arm, Phase 2 Study of Single-Agent Carfilzomib in Patients With Relapsed And/Or Refractory Multiple Myeloma Who Have Been Previously Treated With Bortezomib
    Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M
    Br J Haematol 2012 Sep;158(6):739-48
  • A Phase 1/2 Study of Carfilzomib in Combination With Lenalidomide and Low-Dose Dexamethasone as a Frontline Treatment for Multiple Myeloma
    Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Nordgren B, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R
    Blood 2012 Aug 30;120(9):1801-9
  • An Open-Label, Single-Arm, Phase 2 (PX-171-004) Study of Single-Agent Carfilzomib in Bortezomib-Naive Patients With Relapsed And/Or Refractory Multiple Myeloma
    Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS
    Blood 2012 Jun 14;119(24):5661-70
  • Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, Kaufman JL, Leleu X, Tsao LC, Westland C, Singhal AK, Jagannath S
    J Clin Oncol 2012 Jun 1;30(16):1953-9
  • Lenalidomide After Stem-Cell Transplantation for Multiple Myeloma
    McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C
    N Engl J Med 2012 May 10;366(19):1770-81
  • A Phase 1/2 Study of Chemosensitization With the CXCR4 Antagonist Plerixafor in Relapsed or Refractory Acute Myeloid Leukemia
    Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Vij R, Westervelt P, DiPersio JF
    Blood 2012 Apr 26;119(17):3917-24
  • Reduced Intensity Conditioning Is Superior to Nonmyeloablative Conditioning for Older Chronic Myelogenous Leukemia Patients Undergoing Hematopoietic Cell Transplant During the Tyrosine Kinase Inhibitor Era
    Warlick E, Ahn KW, Pedersen TL, Artz A, de Lima M, Pulsipher M, Akpek G, Aljurf M, Cahn JY, Cairo M, Chen YB, Cooper B, Deol A, Giralt S, Gupta V, Khoury HJ, Kohrt H, Lazarus HM, Lewis I, Olsson R, Pidala J, Savani BN, Seftel M, Socie G, Tallman M, Ustun C, Vij R, Vindelov L, Weisdorf D
    Blood 2012 Apr 26;119(17):4083-90
  • Phase II Trial of the Pan-Deacetylase Inhibitor Panobinostat as a Single Agent in Advanced Relapsed/Refractory Multiple Myeloma
    Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR, Matous J, Vij R, de Magalhaes-Silverman M, Abonour R, Anderson KC, Lonial S
    Leuk Lymphoma 2012 Sep;53(9):1820-3
  • Evolution of Definitions of Response, Progression-Free Survival and Event-Free Survival in Front-Line Studies of Chronic Myeloid Leukemia
    Ansstas G, Vij R
    Leuk Lymphoma 2012 Jul;53(7):1273-81
  • Waldenstrom Macroglobulinemia: A Surveillance, Epidemiology, and End Results Database Review From 1988 to 2005
    Sekhar J, Sanfilippo K, Zhang Q, Trinkaus K, Vij R, Morgensztern D
    Leuk Lymphoma 2012 Aug;53(8):1625-6
  • Trends in Allogeneic Stem Cell Transplantation for Multiple Myeloma: A CIBMTR Analysis
    Kumar S, Zhang MJ, Li P, Dispenzieri A, Milone GA, Lonial S, Krishnan A, Maiolino A, Wirk B, Weiss B, Freytes CO, Vogl DT, Vesole DH, Lazarus HM, Meehan KR, Hamadani M, Lill M, Callander NS, Majhail NS, Wiernik PH, Nath R, Kamble RT, Vij R, Kyle RA, Gale RP, Hari PN
    Blood 2011 Aug 18;118(7):1979-88
  • Combination Decitabine, Arsenic Trioxide, and Ascorbic Acid for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Phase I Study
    Welch JS, Klco JM, Gao F, Procknow E, Uy GL, Stockerl-Goldstein KE, Abboud CN, Westervelt P, DiPersio JF, Hassan A, Cashen AF, Vij R
    Am J Hematol 2011 Sep;86(9):796-800
  • Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated With Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation
    Smeltzer JP, Cashen AF, Zhang Q, Homb A, Dehdashti F, Abboud CN, DiPersio JF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, Bartlett NL, Fehniger TA
    Biol Blood Marrow Transplant 2011 Nov;17(11):1646-52
  • Alkaline Phosphatase Variation During Carfilzomib Treatment Is Associated With Best Response in Multiple Myeloma Patients
    Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang L, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot G
    Eur J Haematol 2011 Jun;86(6):484-487
  • Initial Genome Sequencing and Analysis of Multiple Myeloma
    Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart AK, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TR
    Nature 2011 Mar 24;471(7339):467-72
  • Weekly Bortezomib in Combination With Temsirolimus in Relapsed or Relapsed and Refractory Multiple Myeloma: A Multicentre, Phase 1/2, Open-Label, Dose-Escalation Study
    Ghobrial IM, Weller E, Vij R, Munshi NC, Banwait R, Bagshaw M, Schlossman R, Leduc R, Chuma S, Kunsman J, Laubach J, Jakubowiak AJ, Maiso P, Roccaro A, Armand P, Dollard A, Warren D, Harris B, Poon T, Sam A, Rodig S, Anderson KC, Richardson PG
    Lancet Oncol 2011 Mar;12(3):263-72
  • High Dose Cytarabine Plus Gemtuzumab Ozogamicin for Patients With Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902
    Stone RM, Moser B, Sanford B, Schulman P, Kolitz JE, Allen S, Stock W, Galinsky I, Vij R, Marcucci G, Hurd D, Larson RA
    Leuk Res 2011 Mar;35(3):329-333
  • A Phase 2 Study of High-Dose Lenalidomide as Initial Therapy for Older Patients With Acute Myeloid Leukemia
    Fehniger TA, Uy GL, Trinkaus K, Nelson AD, Demland J, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Westervelt P, DiPersio JF, Vij R
    Blood 2011 Feb 10;117(6):1828-33
  • Efficacy and Tolerability of PTK787/ZK 222584 in a Phase II Study of Post-Transplant Maintenance Therapy in Patients With Multiple Myeloma Following High-Dose Chemotherapy and Autologous Stem Cell Transplant
    Vij R, Ansstas G, Mosley JC, Bryant G, Hassan A, Amador-Ortiz C, Procknow E
    Leuk Lymphoma 2010 Aug;51(8):1577-9
  • P-Glycoprotein Inhibition Using Valspodar (PSC-833) Does Not Improve Outcomes for Patients Younger Than Age 60 Years With Newly Diagnosed Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19808
    Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, Deangelo DJ, Shea TC, Stock W, Baer MR, Hars V, Maharry K, Hoke E, Vardiman JW, Bloomfield CD, Larson RA
    Blood 2010 Sep 2;116(9):1413-1421
  • Salvage Therapy for Acute Myeloid Leukemia With Fludarabine, Cytarabine, and Idarubicin With or Without Gemtuzumab Ozogamicin and With Concurrent or Sequential G-CSF
    Martin MG, Augustin KM, Uy GL, Welch JS, Hladnik L, Goyal S, Tiwari D, Monahan RS, Reichley RM, Cashen AF, Stockerl-Goldstein K, Westervelt P, Abboud CN, DiPersio JF, Vij R
    Am J Hematol 2009 Nov;84(11):733-7
  • A Phase II Study of 5-Day Intravenous Azacitidine in Patients With Myelodysplastic Syndromes
    Martin MG, Walgren RA, Procknow E, Uy GL, Stockerl-Goldstein K, Cashen AF, Westervelt P, Abboud CN, Kreisel F, Augustin K, DiPersio JF, Vij R
    Am J Hematol 2009 Sep;84(9):560-4
  • An Open-Label, Phase 2 Trial of Denosumab in the Treatment of Relapsed or Plateau-Phase Multiple Myeloma
    Vij R, Horvath N, Spencer A, Taylor K, Vadhan-Raj S, Vescio R, Smith J, Qian Y, Yeh H, Jun S
    Am J Hematol 2009 Oct;84(10):650-6
  • Primary Plasma Cell Leukemia: A Surveillance, Epidemiology, and End Results Database Analysis Between 1973 and 2004
    Ramsingh G, Mehan P, Luo J, Vij R, Morgensztern D
    Cancer 2009 Dec 15;115(24):5734-9
  • Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
    Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P, Whitman SP, Mrozek K, Baldus CD, Vij R, Powell BL, Carroll AJ, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD
    J Clin Oncol 2009 Jul 1;27(19):3198-204
  • Prognostic Factors Influencing Survival in Solitary Plasmacytoma
    Ramsingh G, Mehan P, Morgensztern D, Luo J, Vij R
    Br J Haematol 2009 May;145(4):540-2
  • Arterial Thrombosis With Immunomodulatory Derivatives in the Treatment of Multiple Myeloma: A Single-Center Case Series and Review of the Literature
    Martin MG, Vij R
    Clin Lymphoma Myeloma 2009 Aug;9(4):320-3
  • Allo-SCT Conditioning for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Clofarabine, Cytarabine and ATG
    Martin MG, Uy GL, Procknow E, Stockerl-Goldstein K, Cashen A, Westervelt P, Abboud CN, Augustin K, Luo J, DiPersio JF, Vij R
    Bone Marrow Transplant 2009 Jul;44(1):13-7
  • Dasatinib in Relapsed or Plateau-Phase Multiple Myeloma
    Wildes TM, Procknow E, Gao F, DiPersio JF, Vij R
    Leuk Lymphoma 2009 Jan;50(1):137-40
  • Bortezomib Administered Pre-Auto-SCT and as Maintenance Therapy Post Transplant for Multiple Myeloma: A Single Institution Phase II Study
    Uy GL, Goyal SD, Fisher NM, Oza AY, Tomasson MH, Stockerl-Goldstein K, DiPersio JF, Vij R
    Bone Marrow Transplant 2009 May;43(10):793-800
  • Neurobeachin (NBEA) Is a Target of Recurrent Interstitial Deletions at 13q13 in Patients With MGUS and Multiple Myeloma
    O'Neal J, Gao F, Hassan A, Monahan R, Barrios S, Lee I, Chng WJ, Vij R, Tomasson MH
    Exp Hematol 2009 Feb;37(2):234-44
  • Single-Agent Lenalidomide Induces Complete Remission of Acute Myeloid Leukemia in Patients With Isolated Trisomy 13
    Fehniger TA, Byrd JC, Marcucci G, Abboud CN, Kefauver C, Payton JE, Vij R, Blum W
    Blood 2009 Jan 29;113(5):1002-5
  • Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation
    Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF
    Biol Blood Marrow Transplant 2008 Sep;14(9):1045-56
  • Rapid Mobilization of Functional Donor Hematopoietic Cells Without G-CSF Using Plerixafor, an Antagonist of the CXCR4/SDF-1 Interaction
    Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N, Devine H, Link DC, Calandra G, Bridger G, Westervelt P, DiPersio JF
    Blood 2008 Aug 15;112(4):990-8
  • Maribavir Prophylaxis for Prevention of Cytomegalovirus Infection in Allogeneic Stem Cell Transplant Recipients: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study
    Winston DJ, Young JA, Pullarkat V, Papanicolaou GA, Vij R, Vance E, Alangaden GJ, Chemaly RF, Petersen F, Chao N, Klein J, Sprague K, Villano SA, Boeckh M
    Blood 2008 Jun 1;111(11):5403-10
  • Comorbidities, Not Age, Impact Outcomes in Autologous Stem Cell Transplant for Relapsed Non-Hodgkin Lymphoma
    Wildes TM, Augustin KM, Sempek D, Zhang QJ, Vij R, DiPersio JF, Devine SM
    Biol Blood Marrow Transplant 2008 Jul;14(7):840-6
  • Bortezomib Inhibits Osteoclast Activity in Patients With Multiple Myeloma
    Uy GL, Trivedi R, Peles S, Fisher NM, Zhang QJ, Tomasson MH, DiPersio JF, Vij R
    Clin Lymphoma Myeloma 2007 Nov;7(9):587-9
  • A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation
    Fong T, Trinkaus K, Adkins D, Vij R, Devine SM, Tomasson M, Goodnough LT, Lopez S, Graubert T, Shenoy S, DiPersio JF, Khoury HJ
    Biol Blood Marrow Transplant 2007 Oct;13(10):1201-6
  • Prognostic Significance of Early Lymphocyte Recovery After Post-Autografting Administration of GM-CSF in Non-Hodgkin's Lymphoma
    Tiwari D, Gao F, Hidalgo J, Adkins DR, Vij R, DiPersio JF, Khoury HJ
    Bone Marrow Transplant 2007 Oct;40(7):671-5
  • Copper Deficiency: An Important Consideration in the Differential Diagnosis of Myelodysplastic Syndrome
    Fong T, Vij R, Vijayan A, DiPersio J, Blinder M
    Haematologica 2007 Oct;92(10):1429-30
  • The Activity and Toxicity of Low Dose Clofarabine Against Relapsed or Refractory Myeloma
    Uy GL, Tomasson MH, Ruddell A, DiPersio JF, Vij R
    Haematologica 2006 Nov;91(11):1581-2
  • Long-Term Remissions in Patients With Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia Undergoing Allogeneic Transplantation Following a Reduced Intensity Conditioning Regimen of 550 CGy Total Body Irradiation and Cyclophosphamide
    Hallemeier CL, Girgis MD, Blum WG, Brown RA, Khoury HJ, Devine SM, Vij R, Lin HS, DiPersio JF, Adkins DR
    Biol Blood Marrow Transplant 2006 Jul;12(7):749-57
  • Granulocyte-Colony-Stimulating Factor-Mobilized Prophylactic Granulocyte Transfusions Given After Allogeneic Peripheral Blood Progenitor Cell Transplantation Result in a Modest Reduction of Febrile Days and Intravenous Antibiotic Usage
    Oza A, Hallemeier C, Goodnough L, Khoury H, Shenoy S, Devine S, Augustin K, Vij R, Trinkaus K, DiPersio JF, Adkins D
    Transfusion 2006 Jan;46(1):14-23
  • Once Daily Ganciclovir as Initial Pre-Emptive Therapy Delayed Until Threshold CMV Load > or =10000 Copies/Ml: A Safe and Effective Strategy for Allogeneic Stem Cell Transplant Patients
    Verkruyse LA, Storch GA, Devine SM, DiPersio JF, Vij R
    Bone Marrow Transplant 2006 Jan;37(1):51-6
  • West Nile Virus Encephalopathy in an Allogeneic Stem Cell Transplant Recipient: Use of Quantitative PCR for Diagnosis and Assessment of Viral Clearance
    Brenner W, Storch G, Buller R, Vij R, Devine S, DiPersio J
    Bone Marrow Transplant 2005 Aug;36(4):369-70
  • Reduced Risk of Acute GVHD Following Mobilization of HLA-Identical Sibling Donors With GM-CSF Alone
    Devine SM, Brown RA, Mathews V, Trinkaus K, Khoury H, Adkins D, Vij R, Sempek D, Graubert T, Tomasson M, Goodnough LT, DiPersio JF
    Bone Marrow Transplant 2005 Sep;36(6):531-8
  • Pilot Study of 13Cis-Retinoic Acid+Dexamethasone+Alpha Interferon as Maintenance Therapy Following High-Dose Chemotherapy and Autologous Stem Cell Transplant for Multiple Myeloma
    Friedman J, Khoury H, Adkins D, Devine S, Nervi B, Edwards T, DiPersio J, Vij R
    Bone Marrow Transplant 2005 May;35(10):979-84
  • Chimerism and Clinical Outcomes of 110 Recipients of Unrelated Donor Bone Marrow Transplants Who Underwent Conditioning With Low-Dose, Single-Exposure Total Body Irradiation and Cyclophosphamide
    Girgis M, Hallemeier C, Blum W, Brown R, Lin HS, Khoury H, Goodnough LT, Vij R, Devine S, Wehde M, Postma S, Oza A, DiPersio J, Adkins D
    Blood 2005 Apr 15;105(8):3035-41
  • Effects of Pretransplantation Treatment With Rituximab on Outcomes of Autologous Stem-Cell Transplantation for Non-Hodgkin's Lymphoma
    Hoerr AL, Gao F, Hidalgo J, Tiwari D, Blum KA, Mathews V, Adkins DR, Blum W, Devine S, Vij R, Goodnough LT, DiPersio JF, Khoury HJ
    J Clin Oncol 2004 Nov 15;22(22):4561-6
  • Re: High Rate of Graft Failure in 25 Patients With Chronic Myelogenous Leukemia Conditioned With a Reduced-Intensity Regimen of 550 CGy Total Body Irradiation and Cyclophosphamide for Unrelated Donor Transplantation
    Hallemeier C, Girgis M, Khoury H, Devine S, Blum W, Vij R, Lin H-S, DiPersio J, Adkins D
    Biol Blood Marrow Transplant 2004 Oct;10(10):726-7
  • Supraventricular Tachyarrhythmias After Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors and Outcomes
    Hidalgo JD, Krone R, Rich MW, Blum K, Adkins D, Fan MY, Brown R, Devine S, Graubert T, Blum W, Tomasson M, Goodnough LT, Vij R, DiPersio J, Khoury H
    Bone Marrow Transplant 2004 Oct;34(7):615-9
  • Outcomes of Adults With Acute Myelogenous Leukemia in Remission Given 550 CGy of Single-Exposure Total Body Irradiation, Cyclophosphamide, and Unrelated Donor Bone Marrow Transplants
    Hallemeier C, Girgis M, Blum W, Brown R, Khoury H, Goodnough LT, Vij R, Devine S, Wehde M, Postma S, Lin HS, DiPersio J, Adkins D
    Biol Blood Marrow Transplant 2004 May;10(5):310-9
  • Hydroxychloroquine for the Prevention of Acute Graft-Versus-Host Disease After Unrelated Donor Transplantation
    Khoury H, Trinkaus K, Zhang MJ, Adkins D, Brown R, Vij R, Goodnough LT, Ma MK, McLeod HL, Shenoy S, Horowitz M, DiPersio JF
    Biol Blood Marrow Transplant 2003 Nov;9(11):714-21
  • Recent Advances in Allogeneic Hematopoietic Stem-Cell Transplantation
    Devine SM, Adkins DR, Khoury H, Brown RA, Vij R, Blum W, DiPersio JF
    J Lab Clin Med 2003 Jan;141(1):7-32
  • Long-Term Outcomes of Allogeneic Stem Cell Transplant Recipients After Calcineurin Inhibitor-Induced Neurotoxicity
    Chohan R, Vij R, Adkins D, Blum W, Brown R, Tomasson M, Devine S, Graubert T, Goodnough LT, DiPersio JF, Khoury H
    Br J Haematol 2003 Oct;123(1):110-3
  • Primary Amyloidosis Patients With Significant Organ Dysfunction Tolerate Autologous Transplantation After Conditioning With Single-Dose Total Body Irradiation Alone: A Feasibility Study
    Blum W, Khoury H, Lin HS, Vij R, Goodnough LT, Devine S, DiPersio J, Adkins D
    Biol Blood Marrow Transplant 2003 Jun;9(6):397-404
  • Low-Dose Short-Course Intravenous Ganciclovir as Pre-Emptive Therapy for CMV Viremia Post Allo-PBSC Transplantation
    Vij R, Khoury H, Brown R, Goodnough LT, Devine SM, Blum W, Adkins D, DiPersio JF
    Bone Marrow Transplant 2003 Oct;32(7):703-7
  • Granulocyte Transfusions and Cytomegalovirus Infection
    Vij R, DiPersio J, Khoury H, Goodnough LT, Devine SM, Blum W, Adkins D
    Blood 2003;101(12):5091-2
  • Donor CMV Serostatus Has No Impact on CMV Viremia or Disease When Prophylactic Granulocyte Transfusions Are Given Following Allogeneic Peripheral Blood Stem Cell Transplantation
    Vij R, DiPersio JF, Venkatraman P, Trinkaus K, Goodnough LT, Brown RA, Khoury HJ, Devine SM, Oza A, Shenoy S, Blum W, Adkins D
    Blood 2003 Mar 1;101(5):2067-9
  • Low-Dose (550 CGy), Single-Exposure Total Body Irradiation and Cyclophosphamide: Consistent, Durable Engraftment of Related-Donor Peripheral Blood Stem Cells With Low Treatment-Related Mortality and Fatal Organ Toxicity
    Blum W, Brown R, Lin HS, Zehnbauer B, Khoury H, Goodnough LT, Westervelt P, Vij R, DiPersio J, Adkins D
    Biol Blood Marrow Transplant 2002;8(11):608-18
  • Low Incidence of Transplantation-Related Acute Complications in Patients With Chronic Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation With a Low-Dose (550 CGy) Total Body Irradiation Conditioning Regimen
    Khoury H, Adkins D, Brown R, Pence H, Vij R, Goodnough LT, Westervelt P, Trinkaus K, Lin HS, DiPersio Y
    Biol Blood Marrow Transplant 2001;7(6):352-8
  • Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease With Anti-Thymocyte Globulin
    Khoury H, Kashyap A, Adkins DR, Brown RA, Miller G, Vij R, Westervelt P, Trinkaus K, Goodnough LT, Hayashi RJ, Parker P, Forman SJ, DiPersio JF
    Bone Marrow Transplant 2001 May;27(10):1059-64
  • Adverse Side-Effects Associated With G-CSF in Patients With Chronic Myeloid Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
    Khoury H, Adkins D, Brown R, Vij R, Westervelt P, Trinkaus K, Goodnough LT, DiPersio JF
    Bone Marrow Transplant 2000 Jun;25(11):1197-201
  • Effect of Leukocyte Compatibility on Neutrophil Increment After Transfusion of Granulocyte Colony-Stimulating Factor-Mobilized Prophylactic Granulocyte Transfusions and on Clinical Outcomes After Stem Cell Transplantation
    Adkins DR, Goodnough LT, Shenoy S, Brown R, Moellering J, Khoury H, Vij R, DiPersio J
    Blood 2000 Jun 1;95(11):3605-12
  • Resolution of Psoriasis After Allogeneic Bone Marrow Transplantation for Chronic Myelogenous Leukemia: Late Complications of Therapy
    Adkins DR, Abidi MH, Brown RA, Khoury H, Goodnough LT, Vij R, Westervelt P, DiPersio JF
    Bone Marrow Transplant 2000 Dec;26(11):1239-41
  • Innovations in Allogeneic Stem-Cell Transplantation
    DiPersio JF, Khoury H, Haug J, Vij R, Adkins DR, Goodnough LT, Brown RA
    Semin Hematol 2000 Jan;37(1 Suppl 2):33-41
  • Does Early Treatment With High-Dose Methylprednisolone Alter the Course of Hepatic Regimen-Related Toxicity?
    Khoury H, Adkins D, Brown R, Trinkaus K, Vij R, Miller G, Goodnough LT, DiPersio J
    Bone Marrow Transplant 2000 Apr;25(7):737-43
  • Outcomes of High-Dose Chemotherapy and Autologous Stem Cell Transplant in Isolated Locally Recurrent Breast Cancer: A Multicenter Evaluation
    Vij R, DiPersio J, Brown R, Trinkaus K, Abboud C, Meehan KR, Frenette G, Freytes C, Goodnough LT, Khoury H, Ponnuri J, Adkins D
    Bone Marrow Transplant 2000 Nov;26(9):947-53
  • Allogeneic Peripheral Blood Stem Cell Transplantation Following CD34+ Enrichment by Density Gradient Separation
    Vij R, Brown R, Shenoy S, Haug JS, Kaesberg D, Adkins D, Goodnough LT, Khoury H, DiPersio J
    Bone Marrow Transplant 2000 Jun;25(12):1223-8
  • Long-Term Follow-Up of High-Risk Allogeneic Peripheral-Blood Stem-Cell Transplant Recipients: Graft-Versus-Host Disease and Transplant-Related Mortality
    Brown RA, Adkins D, Khoury H, Vij R, Goodnough LT, Shenoy S, DiPersio JF
    J Clin Oncol 1999 Mar;17(3):806-12
  • Outcomes of High-Dose Chemotherapy and Autologous Stem-Cell Transplantation in Stage IIIB Inflammatory Breast Cancer
    Adkins D, Brown R, Trinkaus K, Maziarz R, Luedke S, Freytes C, Needles B, Wienski D, Fracasso P, Pluard T, Moriconi W, Ryan T, Hoelzer K, Safdar S, Rearden T, Rodriguez G, Khoury H, Vij R, DiPersio J
    J Clin Oncol 1999 Jul;17(7):2006-14
  • Unstable Angina in a Peripheral Blood Stem and Progenitor Cell Donor Given Granulocyte-Colony-Stimulating Factor
    Vij R, Adkins DR, Brown RA, Khoury H, DiPersio JF, Goodnough T
    Transfusion 1999 May;39(5):542-3

Invited Reviews and Commentaries

  • Clonal Evolution in Multiple Myeloma
    Fakhri B, Vij R
    Clin Lymphoma Myeloma Leuk 2016 Aug;16S:S130-S134
  • New Approaches to Molecular Imaging of Multiple Myeloma
    Vij R, Fowler KJ, Shokeen M
    J Nucl Med 2016 Jan;57(1):1-4
  • Preparing for a Haplo Tsunami in India
    Vij R
    MAMC Journal of Medical Sciences 2015 Sep
  • Targeted Treatments for Multiple Myeloma: Specific Role of Carfilzomib
    Sugumar D, Keller J, Vij R
    Pharmgenomics Pers Med 2015 Jan 20;8:23-33
  • Freedom From the Infusion Chair
    Vij R
    Value Based Care in Multiple Myeloma 2013 Oct
  • Haematological Cancer: A Step Before the Next Leap?
    Vij R
    Nat Rev Clin Oncol 2013 Nov;10(11):610-2
  • Frontline Therapy for Transplant Eligible and Ineligible Patients
    Vij R
    Considerations in Multiple Myeloma 2012 Oct;5(3)
  • Carfilzomib Promising in Relapsed and Refractory Multiple Myeloma: Expert Insight
    Vij R
    Clinical Oncology 2012 Sep;7(9):20
  • Evolution of the Dosing Rationale for the Phase 2 and 3 Clinical Studies of Carfilzomib
    Kaufman JL, O'Connor OA, Alsina M, Jagannath S, Siegel DS, Badros AZ, Kirk CJ, Wong AF, Vij R
    Cancer Treatment Reviews, submitted
  • Carfilzomib in Multiple Myeloma
    Vij R
    Clin Adv Hematol Oncol 2012 Sep;10(9):591-3
  • Carfilzomib -- A Next-Generation Proteasome Inhibitor for the Treatment of Relapsed And/Or Refractory Multiple Myeloma
    Siegel DS, Vij R, Niesvizky R
    US Oncology & Hematology - Touch Briefings, in press
  • Best of ASCO 2012: Hematological Malignancies - Plasma Cell Dyscrasias, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, & Chronic Lymphocytic Leukemia
    Vij R
    Oncology Times 2012 Jul
  • Best Myeloma Research of 2011
    Vij R
    Oncology Times 2012 Feb;34(3):18
  • How I Treat Patients With Newly Diagnosed Multiple Myeloma Who Are Not Eligible for Clinical Trials
    Vij R
    Oncology Times 2011 Nov;33(22):22,24-26
  • Treatment-Related Adverse Events in Patients With Relapsed/Refractory Multiple Myeloma
    Vij R
    Oncology 2011 Nov;25(2)
  • Overview of Relapsed and Refractory Multiple Myeloma
    Vij R
    Clinical Advances in Hematology & Oncology 2011 Apr;9(4 Suppl 6):4-6
  • Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications
    Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA
    Mayo Clin Proc 2010 Feb;85(2):197-9; author reply 201-4
  • Molecular Pathology of Myeloproliferative Neoplasms
    Klco JM, Vij R, Kreisel FH, Hassan A, Frater JL
    Am J Clin Pathol 2010 Apr;133(4):602-15
  • Clofarabine: A Size That Fits All, May Not Fit All
    Vij R
    Leuk Lymphoma 2009 Mar;50(3):309-10
  • Optimizing the Dasatinib Dose Regimen in Chronic Phase Chronic Myeloid Leukemia (CP CML): 100 Mg Once Daily Available for Use
    Vij R
    Commun Oncol 2009;6:18–20
  • In Defense of High Dose Chemotherapy for Multiple Myeloma
    Vij R
    American Journal of Hematology and Oncology 2007;6(3) suppl 3:17-19
  • Recent Advances in Stem Cell Transplantation
    Vij R
    Medicine Update (Anniversary Issue 2003)
  • WebEBM Clinical Practice Guidelines for Adult Myelodysplastic Syndrome
    Vij R, DiPersio J
    Feb 2002
  • WebEBM Clinical Practice Guidelines for Adult Chronic Lymphoid Leukemia
    Vij R, DiPersio J
    Feb 2002
  • WebEBM Clinical Practice Guidelines for Adult Chronic Myeloid Leukemia
    Vij R, DiPersio J
    Feb 2002
  • WebEBM Clinical Practice Guidelines for Adult Acute Lymphoblastic Leukemia
    Vij R, DiPersio J
    Feb 2002
  • WebEBM Clinical Practice Guidelines for Adult Acute Myeloid Leukemia
    Vij R, DiPersio J
    Feb 2002

Books

  • Contemporary Multiple Myeloma Management
    Vij R
    JayPee Brothers Medical Publishers, 2012

Book Chapters

  • Plasma Cell Neoplasms
    Vij R, Goldsmith SR
    In: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology Review, 5th Edition (Morgensztern D, Govindan R, Devarakonda S, Trikalinos NA, Editors), Wolters Kluwer, Philadelphia, 2022
  • Plasma Cell Dyscrasias
    Goldsmith SR, Vij R
    In: The Washington Manual of Oncology, 4th Edition (Morgensztern D, Ghobadi A, Govindan R, Editors), Wolters Kluwer, Philadelphia, 2022
  • Newly Diagnosed Myeloma in 2020
    Moreau P, Touzeau C, Vij R, Goldsmith SR, Rosko AE
    Am Soc Clin Oncol Educ Book 2020 Mar;40:1-15
  • Bones in Multiple Myeloma: Imaging and Therapy
    Zamagni E, Cavo M, Fakhri B, Vij R, Roodman D
    Am Soc Clin Oncol Educ Book 2018 May 23;(38):638-646
  • Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy
    Krishnan A, Vij R, Keller J, Dhakal B, Hari P
    Am Soc Clin Oncol Educ Book 2016;35:210-21
  • Multiple Myeloma and Plasma Cell Dyscrasias
    Keller J, Vij R
    Washington Manual of Oncology, 3rd edition, Lippincott Williams & Wilkins Publishers, 2014
  • Special Topics in Multiple Myeloma (Special Populations, Adverse Effects and Supportive Therapy)
    Vij R
    Living Medical E-textbook. Projects in Knowledge, April 2013
  • Targeted Treatment of Multiple Myeloma: Proteasome Inhibitors
    Sanfillipo K, Vij R
    Current and Emerging Therapeutics for Multiple Myeloma, Future Science Group E-Book, 2013
  • Plasma Cell Neoplasms
    Vij R, Ramsingh G
    Cancer: Principles and Practices of Oncology Review, 3rd Edition, Wolters Kluwer, Lippincott Williams & Wilkins 2011
  • Essential Cancer Pharmacology, the Prescriber's Guide
    Vij R
    Wolters Kluwer, Lippincott Williams & Wilkins 2009
  • Plasma Cell Neoplasms
    Vij R, Ramsingh G
    Cancer: Principles and Practices of Oncology Review, 2nd Edition (Wolters Kluwer, Lippincott Williams & Wilkins 2009)
  • Multiple Myeloma and Plasma Cell Dyscrasias
    Wildes T, Vij R
    Washington Manual of Oncology, 2nd edition (Lippincott Williams & Wilkins 2008:333-343)
  • Plasma Cell Neoplasms
    Vij R
    Cancer: Principles and Practices of Oncology Review, First Edition. (Lippincott Williams and Wilkins 2005)
  • Combination Chemotherapy Regimen: Multiple Myeloma
    Vij R
    Pocket Guide to Injectable Chemotherapeutic Agents, Fifth Edition (Midwest Book Publishing 2009)
  • Cytokines in Allogeneic Stem Cell Mobilization
    Vij R, DiPersio
    Allogeneic Stem Cell Transplantation Clinical Research and Practice (Humana Press 2003:159-168)
  • Multiple Myeloma and Plasma Cell Dyscrasias
    Read W, Vij R
    Washington Manual of Oncology (Lippincott Williams & Wilkins Publishers 2002:297-309)
  • Principles of High Dose Therapy and Stem Cell Transplantation
    Vij R, Westervelt P, DiPersio J
    Washington Manual of Oncology (Lippincott Williams & Wilkins Publishers 2002:78-99)
  • The Effects of Multilineage Cytokines on Platelet Recovery
    Vij R, DiPersio J
    Clinical Applications of Cytokines and Growth Factors (Kluwer Academic Publishers. 1999: 237-268)